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Abstract 
Background 
A coordinated heart beat relies on the propagation of a rapid depolarising event 
throughout the atria and ventricles and the subsequent coupling of this electrical signal to a 
transient contraction in every atrial and ventricular cardiomyocyte. The rate of 
propagation, known as conduction velocity (CV) is mainly determined by cellular expression 
of Na channels and gap junctional proteins (connexins), however there is emerging 
evidence that both proteins may be functionally regulated by intrinsic signaling processes. 
Previous studies indicate that stimulation of the β-adrenergic pathway increases CV, but 
little consistent data exists on the magnitude, associated adrenoreceptor pharmacology or 
time course of the effect. This study investigates the effect of β-AR stimulation – using 
either the β-agonist isoproterenol (ISO) or by directly raising cAMP via addition of Forskolin 
(Fsk) and/or 3-Isobutyl-1-methylxanthine (IBMX) - on ventricular CV in the intact rat heart. 
The aim was to measure the response of CV to β-AR stimulation and investigate the 
mechanisms behind this response. Action potential (AP) and intracellular Ca2+ 
measurements were also made to determine the effect of β-AR stimulation on cellular 
electrophysiology over the same time-course as the CV response to β-AR stimulation. 
Methods 
Adult male Wistar rats (250-350g) were euthanized by cervical dislocation and excised 
hearts retrogradely perfused with modified Tyrode's solution. CV measurements were 
taken using a custom-built probe, consisting of bipolar stimulating and recording electrode 
pairs placed flat against the epicardium of the left ventricle (LV). The CV probe also 
incorporated a fibre-optic light guide, allowing ratiometric measurements of voltage and 
intracellular Ca2+ from the LV epicardium.  
Results and Conclusions 
β-AR stimulation increased LV longitudinal CV by approximately 10%. This increase in CV 
was found to be cAMP mediated. This effect was not due to changes in Ca2+ handling alone 
and although an increase in AP amplitude (APA) suggested that INa was increased, the 
magnitude was thought insufficient to explain the change in CV. This suggested a potential 
role for gap junction conductance (GJC) in mediating CV changes. This view was supported 
by preliminary data indicating the magnitude of the response was larger when measuring 
transverse CV: transverse conduction involves proportionally more GJC than longitudinal 
conduction. 
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β-AR stimulation was confirmed to increase CV, a response mediated via β1AR subtype, and 
which required an increase in cAMP: cAMP was increased by activation of adenylyl cyclase 
(AC) with forskolin (Fsk) or through inhibition of phosphodiesterases (PDEs) by IBMX.  The 
increase in CV was shown to be mediated through the cAMP sensitive kinase, PKA; another 
cAMP target, Epac, appeared not have a role in this pathway.   
Understanding the regulation of CV by β-AR stimulation is crucial to understanding 
sympathetic regulation of the heart and may lead to further understanding of the interplay 
between downregulated β-AR signaling and arrhythmia generation in the diseased heart. 
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1. Introduction 
1.1 The heart as a functional syncytium 
A coordinated heart beat relies on the propagation of a rapid electrical depolarising event, 
the action potential (AP), throughout the atria and ventricles and the subsequent coupling 
of this electrical signal to a transient contraction in every atrial and ventricular 
cardiomyocyte. Adult cardiomyocytes are elongated cells approximately 0.12mm long and 
0.02mm in diameter. The contractile proteins within the cells are arranged longitudinally 
and the associated longitudinal mechanical force is transmitted to adjacent cells via 
complex bridging structures at the end of cells known as intercalated discs. These 
structures contain protein complexes called zona-adherins that provide mechanical cell-to-
cell linkages (Giepmans, 2004) and specialised structures, termed gap-junctions (GJs),that 
allow the electrical coupling of adjacent cells by linking adjacent surface membranes with a 
protein channel. Clusters of GJs (called plaques) appear at the intercalated disc and to a 
lesser extent along the lateral membranes of the heart cells (Palatinus et al., 2012; 
Verheule et al., 1997).  
1.2 The Cardiac AP 
1.2.1 The Ventricular AP 
The cardiac AP is the membrane potential (Em) waveform which leads to the raise in 
intracellular [Ca2+] that ultimately leads to contraction of the myocyte. It is created by the 
interplay of the many different ion channels and transporters present in the myocyte, and 
it has different properties in different regions of the heart. As this thesis focuses on 
conduction within the myocardium, this introduction will focus on the properties of the 
ventricular AP. 
The ventricular AP has a stable resting Em of -80mV and is primarily maintained by IK1 
channels (Levick, 2000). The resting cardiac myocyte is preferentially permeable to K and Em 
is therefore close to the equilibrium potential (or Nernst potential) for K+: it is not exactly 
the Nernst potential for K+ (-89mV) as the cardiac myocyte contains many ion channels and 
is not impermeable other ions (Bers, 2001; Kaneshiro, 2011). The ventricular AP has a rapid 
upstroke driven largely by activation of voltage sensitive Na+ channels which reaches 
between +30-50mV, followed by the characteristic ‘notch’ and a prominent plateau phase 
(Bers, 2001). The AP is triggered by current spread from neighbouring activated 
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myocardium: this current spread is passive and occurs primarily through gap junctions, as 
discussed in section 1.8. This causes the depolarisation of the Em to a threshold where 
enough Na+ channels are activated that INa>IK (Kléber and Rudy, 2004). 
The long APD of the ventricular AP is due to the plateau phase: the plateau phase is a phase 
in the AP where the Em does not change rapidly. It maintains depolarisation, preventing 
reactivation of Na+ and Ca2+ channels and therefore preventing electrical re-excitation 
(Bers, 2001). 
An outline of the rabbit ventricular AP taken from Bers 2001 and the main ionic currents 
behind it is shown below (Fig. 1.2.1; Bers, 2001). There are 4 main phases to the AP which 
are outlined below: 
Phase 0: Rapid upstroke 
Passive spread of current from activated regions depolarises the membrane and leads to 
activation of voltage sensitive Na+ channels (Nav1.5), causing a rapid increase in INa and 
depolarising of Em to ~30-50mV. Depolarising Em also inactivates IK1 and activates voltage 
sensitive Ca2+ channels (CaL). At the AP peak, INa is at its maximum activation and ICa is at 
43% of maximum.  
Phase 1: Early Repolarisation 
This is characterised by the ‘notch’ seen in the cardiac AP. Nav1.5 channels rapidly 
inactivate (this is further explained in 1.2.3) and Ito and ICa(Cl) are activated. Sarcoplasmic 
reticulum Ca2+ release causes inactivation of ICa. 
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Figure 1.2.1: Calculated Em, ionic currents and [Ca]I during a rabbit AP, taken from Bers, 2001.  
This figure shows the rabbit ventricular AP alongside the ionic currents which generate the AP. 
  
Annabel Campbell 2017 
 
    18 
 
Phase 2: Plateau Phase 
Em does not change rapidly during the plateau phase. This phase is governed primarily by a 
combination of inward ICaL and outward delayed rectifier K+ currents (IKur, IKs and IKr),: the 
net influence of this is that there is little change in overall Em. 
Phase 3: Late Repolarisation 
During late repolarisation, Em rapidly repolarises back to resting Em. As repolarisation 
increases, IKr increases, accelerating repolarisation. At more negative Em, IKr inactivates and 
IK1 reactivates (at around -30mV). INa/Ca acts in the direction of Ca2+ extrusion, due to high 
intracellular [Ca2+]. 
1.2.2 Cardiac Ion channels 
The waveform of the cardiac AP is determined by of ion channels and transporters, the 
activity of which alter Em. Ions carry a charge and therefore cannot easily cross the 
hydrophobic lipid bilayer and require membrane translocators – in the form of ion 
channels, transporters or exchangers – to cross the cell membrane. Ion channels are 
complex protein channels in the cell membrane that provide an aqueous pore which allows 
the diffusion of ions across the cell membrane along their electrochemical gradient. The 
movement of ions across the membrane is ionic current, dennoted as ‘I’ (Aidley, 2008; Jalife 
et al., 2009; Kaneshiro, 2011).  
 Ion channels are characterised by two main properties:  
i) Gating: the ability to exist in an opened or closed state. This occurs in response 
to appropriate stimulus: this stimulus can be electrical (voltage-gated); 
chemical (ligand gated) or mechanical (stretch). Switching between an open 
and closed state requires a conformational change in the channel which alters 
the conductance of the channel, denoted as ‘g’ (Catterall, 2012; de Lera Ruiz and 
Kraus, 2015) An example of voltage gating – the voltage-gated Na+ channel – is 
explained below (1.2.3). 
ii) Selectivity: ion channels discriminate between different species of ion, allowing 
the diffusion of particular ions across the membrane (Catterall, 2012). Again, a 
detailed example of ion channel selectivity is discussed below using Nav1.5 as 
an example.  
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1.2.3 The Voltage Sensitive Na channel 
The amplitude and shape of the AP is a major determinant of conduction in the heart, 
particularly phase 0: the upstoke (this is further discussed in 1.6). INa and the availability of 
Na+ channels are a major determinate of membrane excitability and form the ‘source’ for 
cardiac propagation (Kléber and Rudy, 2004). Therefore, for this thesis it is important to 
understand the structure and function of the voltage-gated Na+ channel (NaV1.5). Voltage-
gated Ca2+ channels and some K+ channels share a similar structure to NaV1.5 (Bers, 2001). 
Voltage-gated Na+ currents were originally discovered in the giant squid axon by Hodgkin 
and Huxley in 1952 (Hodgkin and Huxley, 1952). Na+ channels were found to have 3 states: 
closed (resting); open conducting; inactivated. 
The voltage-gated Na+ channel is composed of one α subunit and 1 or 2 β subunits. There 
are nine subtypes of α subunit: NaV1.5 is the α subunit expressed in cardiac tissue. NaV1.5 is 
a single chain polypeptide 260kDa in size. It contains 4 homologous domains arranged in a 
pseudotetramic structure: DI-DIV. Each of these domains contains 6 transmembrane 
domains (S1-S6) (Catterall, 2012). 
As previously discussed in 1.2.2, NaV1.5 is a voltage gated channel. It is in the closed state 
at the resting membrane potential of -80mV. On depolarisation, the Na+ channel opens. 
The voltage sensors of the Na+ channel is composed of transmembrane α segments S1-4. 
The four voltage sensing domains are arranged around the central aqueous pore. The S4 
domain is positively charged and lies at the centre of the pore. On depolarisation, it is 
believed that the S4 domain moves towards the extracellular surface (Yang et al., 1996): the 
voltage sensitive domains are flexible as they contain a positively charged arginine and 
lysine for every third amino acid (Catterall, 1988). Linkers between the voltage sensitive 
segments and the pore confer a conformational change to the pore, switching the channel 
into the ‘open’ state. This allows the movement of Na+ down its electrochemical gradient 
into the cell – this gradient is established by the Na-K ATPase (de Lera Ruiz and Kraus, 2015). 
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Fig. 1.2.3: Nav channel architecture (Lera Ruiz de and Kraus, 2015) 
 (A) Topology of the human NaV α subunits. (B) Extracellular view of the open-channel conformation 
crystal structure of NaVMs, a marine bacterium from Magnetococcus sp. (C) Side view of the open-
channel conformation crystal structure of bacterial NaVMs, showing the selectivity filter and 
activation gate. 
During depolarisation, inactivation of the Na+ channel occurs rapidly due to the inactivation 
gate. This consists of the intracellular loop connecting DIII and DIV: this loops forms a 
‘hinged lid’ which is believed to fold into the centre of the pore during inactivation. This 
cause the ‘rapid’ inactivation of Na+ channels (Catterall, 2012; de Lera Ruiz and Kraus, 2015). 
Membrane repolarisation is required for the reactivation of NaV1.5 – therefore Na+ 
channels are inactive during the AP and a second activation of the myocyte cannot be 
elicited (absolute refractory period). The rate at which Na+ channels recover depends on 
how negative the Em is. Therefore, the more negative the Em, the faster the recovery of Na+ 
channels and the higher the Na+ channel availability (Bers, 2001). 
The pore itself is composed of the S5 and S6 transmembrane helices and the extracellular 
connecting pore loops. The pore confers the ion selectivity of the Na+ channel. Ion 
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selectivity in part relies on steric hindrance: the narrowest part of the pore is 3.5x5.1Å and 
allows hydrated Na+ ions to pass through the channel. However, this cannot entirely 
explain ion selectivity, otherwise smaller ions would be able to pass freely through the Na+ 
channel. It also relies on liganding of ions to specific sites on the pore where energy 
conditions favour the binding of the ion to which the channel is permeable (Aidley, 2008). 
An extracellular outer ring screens for Na+ and repels it towards a highly Na+ selective 
location within the pore. This is formed of the hydroxyl groups of aspartate and glutamate 
(de Lera Ruiz and Kraus, 2015). 
1.2.4 Species differences in the cardiac AP 
The animal model used in this thesis is the rat. The rat is a well-established model and 
widely used model for studying cardiac electrophysiology. However, there are differences 
between the electrophysiology of the rat compared with larger mammals. These are 
particularly apparent in the AP shape and duration: rat APs lack the notch and plateau 
phase seen in humans and larger mammals such as rabbit and dog (Fig 2.1.2). The rat has a 
much greater Ito than larger mammals, leading to rapid early repolarisation. The extent of 
this early repolarisation eliminates the plateau phase seen in larger mammals (Bers, 2001). 
Late repolarisation is also different in rats compared to larger mammals due to the 
contribution of IKs and IKr: these currents are much smaller in the rat and contribute far less 
to repolarisation (Varró et al., 1993). This is particularly important when considering the 
effect of β-AR signalling on the AP, as β-AR increases IKs and therefore shortens the AP in 
large mammals – this is not observed in rat due to the rat AP’s rapid repolarisation (Walsh 
et al., 1988; Walsh and Kass, 1988). 
However, for studying propagation of the AP, the rat is still a valid model. NaV1.5 is highly 
conserved across species, and the upstroke of AP is the component most likely to 
contribute to CV. Ventricular CV is between 60cm/s and 80cm/s longitudinally with little 
variation between species (Draper and Mya-Tu, 1959). Connexins – the proteins from 
which gap junctions are composed – are also conserved across species. It is well established 
that the main Cx in the ventricle is Cx43, and although there is differential expression of 
Cx43 the atria, Cx43 is similarly expressed in the ventricle in human and other mammals, 
including rat (Gros and Jongsma, 1996; van Kempen et al., 1995; Vozzi et al., 1999). This 
makes the rat a suitable model for the study of ventricular CV.  
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Fig 1.2.4 APs across species.  
 
Example APs recorded from rat A) and rabbit B) recorded by ME in lab.  C) Example dog ventricle AP 
recorded in isolated cells (Kääb et al., 1996). D) Example human APs recorded from isolated human 
cells (Näbauer et al., 1996). 
 
1.3 Conduction of Action Potentials in the Ventricle 
Cardiac APs propagate along the length of a single cardiomyocyte at approximately 
100cm/sec (Cheng et al., 1999); this speed is dictated by the AP shape, particularly the 
leading phase, and the electrical cable properties of the cell, including the electrical 
resistance due to the intracellular space (approximately 5MΩ for a cell 0.12mm long)(Rohr, 
2004). The resistance of the link between cells provided by the GJs within the intercalated 
disc is a factor of ~104x higher than a comparable length of continuous cytosol (Rohr, 
2004). However, the distance that GJs span between cells is ~10-4x the length of the cell, 
thus the resistance between adjacent cells (5MΩ) is comparable to the resistance along the 
length of one cardiomyocyte (5MΩ). On this basis, the overall resistance of a series of 
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cardiomyocytes linked end-to-end is only ~2X that of a single cell of equivalent length and 
therefore the conduction velocity (CV) is ~1/√2 X 100cm/sec, i.e. approximately 70cm/sec. 
As demonstrated using computational models (Jongsma et al., 1999; Shaw and Rudy, 1997), 
the dependence of CV on the conductance of GJs is non-linear, with CV being proportional 
to GJ conductance to the power 0.28: i.e. doubling of GJ conductance would increase CV by 
approximately 12%. This analysis applies to longitudinal conduction model, where the 
intercellular resistance is equally distributed between intercalated disc and intracellular 
resistances. However, conduction transverse to the fibre axis has a larger contribution from 
intercalated disc resistances relative to the cytoplasmic component for an equivalent 
distance. Therefore, the effect of changes in overall GJ conductance on CV may be larger in 
the transverse axis.  
A second determinant of CV is the amplitude and shape of the cardiac AP. In particular, CV 
depends on the rate of depolarisation, which is approximately sigmoidal in time course, 
rising from 10% to 90% of maximum in 1-2ms with a maximum rate of rise (dV/dtmax) of 
~0.1V/msec. Computational modelling has shown that CV is proportional to dV/dtmax (and 
AP amplitude) raised to the power ~0.5 (Cohen et al., 1981) i.e. doubling dV/dtmax would 
increase CV by approximately 22%. 
Recently studies have shown high levels of Na channels (type NaV 1.5) in the regions of the 
intercalated disc near connexins. This raises the possibility that Na current flow at one 
membrane surface could generate negative potential in the narrow gap between cells at 
the intercalated disc and the subsequent electric field could influence membrane potential 
of the adjacent cell (Kucera et al., 2002). The same arguments apply to the movement of 
potassium within the limited extracellular space; this type of transmission between cells 
(i.e. not involving net ion current flow between cells) is termed ephaptic and the role of this 
form of cell-to-cell transmission relative to that mediated via gap-junctions is not known 
(Veeraraghavan et al., 2014). Some studies suggest that ephaptic transmission between 
adjacent cells is a significant consideration when coupling via gap-junctions is below normal 
e.g. under ischaemic conditions, in the presence of connexin-blocking drugs 
(Veeraraghavan et al., 2012) or after significant down-regulation of connexin expression. 
The ventricular wall has a complex 3D structure containing bundles of cardiac myocytes 
surrounded by a connective tissue sheath and arranged in regular sheets termed 
“laminae”, with the myocytes within these laminae connected end-to-end. On the 
epicardial surface, these sheets are arranged such that the fibre orientation (long-axis of 
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the cells) is parallel with the surface and runs approximately 90o to the vertical axis. This 
angle changes progressively in the myocardial layers between epicardial and endocardial 
surfaces. By the mid-myocardium, fibre orientation is approximately vertical and by the 
endocardial surface fibre orientation has turned by another 90o (Gilbert et al., 2011). During 
a normal cardiac cycle, the activation sequence of the free wall of the right and left 
ventricles consists of an initial rapid conduction of the AP over the endocardial surface via 
the Purkinje fibre network followed by propagation through the wall of the ventricle from 
endocardial to epicardial surfaces via cardiomyocyte-to-cardiomyocyte conduction. As 
longitudinal fibre orientation runs parallel to the surface of the heart, the conduction from 
endo to epicardium is at a direction transverse to the fibre axis (Gilbert et al., 2012): The 
speed of transverse propagation (i.e. 90o to the fibre axis) is approximately 1/2 that along 
the fibre axis (longitudinal propagation) (Roberts et al., 1979); this is thought to be due to 
the greater number of gap-junctions (per unit length) transverse to the fibre axis. 
Therefore, propagation velocity for this final phase of ventricular activation surface is slow 
(approximately 35cm/sec). For example, in a human left ventricle wall (1-1.5cm in 
thickness), propagation will take 0.03-0.05s, i.e. a major fraction of the total QRS duration 
(0.06-0.1s). 
Analysis of the timing of different phases of the electrocardiogram indicate significant 
shortening of the QRS duration during exercise, which is explained in terms of decreased 
ventricular activation time due to increased CV (Goldberger et al., 1994; Pilhall et al., 1993). 
These studies showed a decrease of QRS duration by approximately 10% during mild 
exercise (heart rate approximately 140bpm) in normal healthy adults. The QRS duration is a 
parameter that can be influenced by a series of factors other than ventricular CV e.g. 
Purkinje fibre propagation velocity and position and geometry of the heart, but the 
contribution of increased ventricular CV due to the influence of autonomic nervous system 
has not been properly investigated. 
Interventions which increase heart rate do so through reciprocal changes in activity of the 
parasympathetic and sympathetic nerves and therefore the effects on the ventricular 
electrophysiology could be via decreased parasympathetic as well as increased sympathetic 
activity (Brack et al., 2013b). Furthermore, sympathetic nerves release other 
neurotransmitters such as neuropeptide Y as well as norepinephrine (Potter, 1988). Thus 
examining the physiology of autonomic influences is complex; this study is focused on the 
potential effects of activation of adrenoreceptors on ventricular electrophysiology as one 
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of the dominant influences on the heart, but it should be recognised that the physiological 
response is more complex. 
1.4 The effect of adrenergic stimulation on ventricular conduction 
velocity in the intact heart 
Most reports of direct measurement of ventricular CV during adrenergic stimulation were 
published in the 1950s and 60s. These studies were carried out exclusively in dog and 
looked at the CV response to superfusion of epinephrine and norepinephrine. They showed 
increased AV-node CV and shortening of its functional refractory period by 40% in response 
to epinephrine in vivo, alongside an increase in ventricular CV (Krayer et al., 1951; Siebens 
et al., 1953). Decreased ventricular conduction time over the right ventricular epicardial 
surface in response to epinephrine has also been noted in dog (Mendez et al., 1964), 
though this study did not differentiate between changes in Purkinje fibre and myocardial 
conduction. As these studies adminstered catelcholamines in vivo, effects of epinephrine 
remote from the heart can occur making the direct effect of epinephrine on the heart less 
clear (Siebens et al., 1953; Williams et al., 1972) rather than a direct effect on the heart. In 
subsequent measurements on isolated dog heart-lung preparations, only small and 
inconsistent increases in ventricular CV were recorded following epinephrine 
administration (Swain and Weidner, 1957). 
Research has also been carried out looking at direct stimulation of the sympathetic nervous 
system of the heart. Stimulation of the left stellate ganglion caused an increase in 
intraventricular CV of approximately 6% (Wallace and Sarnoff, 1964) suggesting direct 
effects of sympathetic innervation to the heart. A more recent study on isolated rabbit 
heart with an intact sympathetic innervation described an instantaneous decrease in 
conduction delay of approximately 30% during sympathetic nerve stimulation but the 
conduction pathway would have included both ventricle and Purkinje fibres (Ng et al., 
2007). As mentioned above, it is important to consider that stimulation of the sympathetic 
nervous system may also include the activation of pathways other than the β-adrenergic 
pathway. However, this thesis will focus on the specific effects of the β-AR pathway on 
conduction. 
More recently, the effect of β-stimulation on Purkinje fibre electrophysiology recorded an 
increase in CV of ~10% without any significant change in the Vmax of the AP upstroke 
(Gintant and Liu, 1992; Munger et al., 1994). However, due to the relatively short time 
involving Purkinje fibre conduction, a 10% increase in CV would be anticipated to have a 
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small effect on the QRS duration, which is primarily influenced by propagation through the 
myocardium. 
In summary, the few studies directly measuring CV within the ventricular myocardium 
indicate an increased CV during activation of the β-AR pathway, but little consistent data 
exists on the magnitude, associated adrenoreceptor pharmacology or time course of the 
effect. 
-Adrenergic signalling in the heart 
Sympathetic nerves release norepinephrine which binds to predominately β-
adrenoreceptors (β-ARs), sub-types β1 and β2, causing an increase in force of contraction 
(positive inotropy) and rate of relaxation (positive lusitropy). The summation of all these 
effects results in a rapid increase in pump function via increased heart rate and increased 
force of contraction. In normal human ventricular muscle, β1-ARs are the predominant 
form (~70% β1:30% β2) (Mendez et al., 1964) and are expressed in both cell surface and T-
tubular membranes (Nikolaev et al., 2010). β1-adrenergic receptors are linked via Gs 
proteins to adenylyl cyclase (AC), and ligand binding to these receptors leads to activation 
of AC and production of the second messenger, cyclic adenosine monophosphate (cAMP). 
Protein kinase A (PKA) is activated by cAMP and has many targets in the heart, including 
multiple ion channels and components of EC-coupling (Hicks et al., 1979; Lehnart and 
Marks, 2007; Marx et al., 2000; Yue et al., 1990). cAMP also signals via the exchange 
proteins activated by cAMP (Epac) (Bos, 2006, 2003; Métrich et al., 2008) and by binding 
directly to ion channels activated by Camp (DiFrancesco and Tortora, 1991). Desensitisation 
of cAMP signals is undertaken by a superfamily of enzymes known as phosphodiesterases 
that hydrolyse the second messenger (Baillie et al., 2007). 
It is important to consider that multiple signalling pathways use cAMP as an intracellular 
messenger, for example prostaglandin E1 causes an increase in cellular cAMP 
concentrations comparable to that seen following β-AR stimulation (Hayes et al., 1979), but 
the effects of the independent addition of the two agonists on cardiac function is not the 
same. This data suggested and subsequent studies have gone on to show that cAMP and its 
effector proteins are compartmentalised within the cell (Baillie, 2009; Vila Petroff et al., 
2001). This results in agonist-specific increases of cAMP within certain discrete 
microdomains, allowing local cAMP -mediated effects (Fischmeister et al., 2006; Mongillo 
et al., 2004; Zaccolo et al., 2001).  
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1.6 The effect of β-stimulation on the upstroke of the ventricular 
action potential. 
The amplitude and shape of the cardiac AP is a major determinant of CV, particularly phase 
0: the AP upstroke (Buchanan et al., 1985; Kléber and Rudy, 2004). This phase of the AP is 
caused by activation of voltage dependent sodium channels. These channels are substrates 
for phosphorylation by PKA (Catterall, 1988; Rossie and Catterall, 1987) and several studies 
have shown that β-AR stimulation causes an increase in the magnitude of the voltage-
sensitive sodium current (INa) and the AP dV/dtmax (Frohnwieser et al., 1997; Lu et al., 1999; 
Matsuda et al., 1992; Schreibmayer et al., 1994; Wang et al., 1996). Other work has 
demonstrated that INa is increased by the action of Ca/CaM-dependent protein kinase II 
(CaMKII) (Jost et al., 2005). β-AR signalling also influences AP duration (APD) and the 
relationship between APD and the diastolic interval (restitution). However, the regulation 
of APD by β-AR signalling is complex; the slowly activating delayed rectifier K+ channel (IKs) 
is a substrate for phosphorylation by PKA; in large mammals, but not rats and mice, β-AR 
stimulation increases IKs which promotes APD shortening (Jost et al., 2005; Volders et al., 
2003). In whole hearts, sympathetic nerve stimulation or addition of β-agonists increases 
the steepness of the slope of the APD restitution curve and reduces the effective refractory 
period (Ng et al., 2007; Taggart et al., 2003). Therefore, the effects of β-AR on the upstroke 
of the AP are a combination of direct effects on INa and indirect effects via the diastolic 
interval that are difficult to predict and have not been measured systematically. 
The availability of INa during the AP upstroke is also limited by the duration of the preceding 
diastolic interval (DI). The normal positive chronotropic response associated with B-AR 
stimulation would naturally shorten the DI and hence reduce INa reactivation. But as 
described above, APD will shorten both due to the intrinsic rate dependence and the 
activation of IKs, both effects helping to maximise the DI and recovery of INa at higher heart 
rates. 
By examining the relationship between INa, dV/dtmax and CV, estimates can be made of the 
maximal possible effects of β-AR stimulation of CV via INa. The measured maximal effect of 
isoprenaline on INa reported is variable but on average isoprenaline increased the current 
by 30-40% (Frohnwieser et al., 1997; Lu et al., 1999; Matsuda et al., 1992; Schreibmayer et 
al., 1994; Wang et al., 1996). The relationship between INa and dV/dtmax is approximately 
linear (Cohen et al., 1984; Kléber and Rudy, 2004); according to both theoretical and 
experimental studies a 40% increase in INa would increase dV/dtmax by approximately 20%. 
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Several studies have shown that in intact ventricle dV/dtmax is proportional to 
CV2(Buchanan et al., 1985; Cohen et al., 1984), therefore an estimate of the maximal effect 
on CV following β-AR stimulation of INa is an increase of only 4-5%. This requires 
experimental validation, but it suggests a limit in the extent to which CV may be increased 
solely through changes in INa.  These results assume that the myocardium can be described 
by a continuous cable, but work by Spach has shown that relationship between dV/dtmax 
and CV is more complex on the surface of the myocardium (Spach and Dolber, 1986). 
Recently this relationship was examined using AP measurements in all 3 dimensions of the 
myocardium. The study concluded that dV/dtmax was unaffected by propagation direction 
deep within the myocardium and that AP rise time was dictated by a balance between INa 
and the downstream axial current developed by the myocardium (Kelly et al., 2013). 
Given the well documented effects of β-AR stimulation on the amplitude of the L-type Ca2+ 
channel current (LTCC), it is relevant to consider the role of this ionic conductance in 
determining propagation velocity. Under normal conditions, the role of INa is dominant; but 
under conditions of reduced excitability - e.g. chronic depolarisation when INa may be 
reduced to <30% of control values - LTCC activity makes a significant contribution to the 
upstroke of the AP and therefore CV. Therefore, modulation of this by β-AR stimulation 
may result in a marked increase in velocity as amplitude of LTCC is increased (Kléber and 
Rudy, 2004; Shaw and Rudy, 1997). 
1.7 The effect of adrenergic signalling on intracellular resistance. 
Low resistance channels between adjacent caridiomyocytes were first identified in 1975 by 
Silvio Weidmann’s group (Weingart et al., 1975). Measurement of intracellular 
conductances/resistances during adrenergic stimulation is technically difficult and only a 
few studies have examined this directly. Intercellular conductance between pairs of 
neonatal cardiac myocytes increased rapidly by approximately 50% on addition of 
isoprenaline or dibutyryl cAMP (dbcAMP) (Burt and Spray, 1988). Other studies simply 
inferred intracellular resistance from CV measurements and examined the effects of more 
long-term stimulation. For example, a large increase in conduction velocity (~25%) in 
response to 24 hrs incubation with dbcAMP was reported in cultured rat neonatal cells 
(Darrow et al., 1996). This was accompanied by an increase in both Cx43 and Cx45 
expression within the first 4 hours of exposure to dbcAMP and a causal link was suggested 
since no significant change in dV/dtmax was observed. However, more recent studies using a 
similar protocol on rat neonatal cardiomyocytes showed an increase in CV and dV/dtmax in 
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response to ISO (de Boer et al., 2007). This suggests INa is increased alongside any potential 
changes in intercellular resistance and therefore the potential role of β-AR mediated 
changes in gap junction conductance are difficult to assess. 
1.8 Gap junctions and Connexins 
Gap junctions are composed of clusters of thousands of GJ channels (Bruzzone et al., 1996). 
These consist of two opposing connexon hemichannels docked end to end, one provided by 
each of the adjacent cells (Maeda and Tsukihara, 2011; Segretain and Falk, 2004). The 
connexons form a channel which allows the diffusion of ions and proteins up to 1000Da in 
size, and provide a low resistance pathway for the propagation of electrical impulses 
between adjacent cells (Verheule et al., 1997). 
Each connexon is made up of six connexin subunits: connexins (Cx) are proteins with four 
transmembrane domains, two extracellular loops and a long intracellular C terminal tail 
(Bruzzone et al., 1996; Maeda and Tsukihara, 2011; Segretain and Falk, 2004). The Cxs are 
arranged in a cylinder surrounding a central hydrophilic pore which is tilted along its axis 
(Unwin and Zampighi, 1980; Yeager, 1998). It has been suggested that sliding or tilting of 
the subunits may close the pore, though 'ball and chain' type gating mechanisms have also 
been suggested for some Cx isoforms (Maeda and Tsukihara, 2011). There are at least 21 
different isoforms of Cx and connexons can be homo- or heteromeric, consisting of more 
than one type of Cx (Giepmans, 2004). Cxs are ubiquitously expressed in a number of 
tissues, electrically and chemically coupling cells throughout the body. Cxs play roles in cell 
signalling (Bedner et al., 2003; Bruzzone et al., 1996), embryonic development (Wei et al., 
2004), and electrically couple neurons, cardiac myocytes and retinal cells. Cxs are 
synthesised and assembled into the GJ hemi-channels, connexons, in the endoplasmic 
reticulum (Segretain and Falk, 2004). It has been suggested that Cx43 is an exception to this 
and is assembled in the trans-golgi network (TGN) (Vanslyke et al., 2009). Connexons are 
then transported through the golgi stacks to the TGN, where they can be stored or 
transported to the plasma membrane in vesicles. Cx assembly into connexons occurs 
before the proteins reach the plasma membrane, allowing incorrectly folded or assembled 
connexons to be transported to the endoplasmic reticulum for degradation, before 
insertion into the membrane (Bruzzone et al., 1996). Docking of two connexons, one from 
each of the adjacent cells, forms the gap junction channel (Yeager, 1998). This occurs 
through hydrogen bonding between residues of the extracellular loops: these amino acids 
are highly conserved in different Cx isoforms (Maeda and Tsukihara, 2011). 
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Figure 1.8.1. Gap junctions and the intercalated disc: 
Diagram showing the organisation of cardiac myocytes and their communication via the intercalated 
disc. The intercalated disc contains GJs plaques - made up of 1000s of GJ channels - through which 
adjacent cells communicate, alongside physical junctions, such as desmosomes and adherens 
junctions. GJ channels themselves are composed of connexon dimers, with one connexon provided by 
each of the adjacent cells. Each connexon is composed of 6 connexins. 
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Once gap junction channels are formed, they cannot be separated into individual connexon 
hemi-channels (Goodenough and Gilula, 1974). This means the entire channel is 
internalised for degradation. Both the lysosomal and proteosomal pathways play a role in 
degradation of connexons (Dunn et al., 2012; Segretain and Falk, 2004). It has been 
suggested that active proteosomal degradation may play a role in the degradation of 
phosphorylated Cxs (Beardslee et al., 1998) and that gap junctional conductance (GJC) can 
be regulated at the level of Cx turnover (Musil et al., 2000). 
1.9 Regulation of connexins 
Physiologically, GJ function in cardiac muscle is regulated via altering Cx levels, localisation 
and opening of GJ channels. Cx43 turnover in the heart is dynamic: studies using 
radioactive labelling have demonstrated that Cx43 has a half life of only 1-2hrs (Beardslee 
et al., 1998; Laird et al., 1991). The short half-life of Cx43 allows dynamic regulation of Cx 
expression, synthesis and degradation, which may rapidly alter levels of Cx at the 
intercalated disc: this may, therefore, influence GJC. Cx43 is also post-translationally 
modified by various intracellular kinases; this allows rapid regulation of Cx43 channel 
formation and behavior (Lampe and Lau, 2004). 
Cx open probability is altered by intracellular Ca2+ and H+ concentrations (Ek-Vitorín et al., 
1996, p.; Liu et al., 1993) and by various forms of post-translational modification 
(Johnstone et al., 2012). Cx43 is a phosphoprotein, which is phosphorylated at multiple 
different sites on the C-terminal tail by kinases including PKA, PKC, PKG and MAPK (Lampe 
and Lau, 2004; Márquez-Rosado et al., 2012; Solan and Lampe, 2009). Mass spectrometry 
has also shown that Cx is variably phosphorylated throughout its lifetime (Chen et al., 2013) 
and its phosphorylation state has been suggested to play a role in almost every aspect of Cx 
life-cycle and function (Jongsma et al., 1999). 
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Figure 1.9.1. Schematic of Cx43 and known regulatory sites  
Diagram showing the C terminal tail of Cx43 and previously established phosphorylation sites located 
in this region (Lampe and Lau, 2004). 
Multiple signalling cascades play a role in the regulation of Cx43. PKC and MAPK have been 
shown to increase the probability of Cx being in a 'closed' state, reducing GJC (Johnstone et 
al., 2012), and have also been shown to play a role in Cx internalisation and degradation 
(Saffitz et al., 2000). The role of PKA mediated phosphorylation, and therefore β-AR 
mediated regulation of Cx43, is less clear: Cx43 has multiple PKA consensus sites in its C-
terminal tail but the protein is considered a relatively poor substrate for PKA (TenBroek et 
al., 2001).  
1.10 Connexins in the heart 
In the heart, the main isoforms of Cx expressed are Cx 43, Cx 40, Cx 37 and Cx 45 (Vozzi et 
al., 1999). Cx43 is the most abundant Cx and is expressed in all four chambers: it is the main 
Cx expressed in the ventricles, though Cx37, Cx40 and Cx45 are also expressed at lower 
levels (Vozzi et al., 1999). Cx40 is expressed mainly in the cardiac conduction system, at 
levels at least three-fold higher in the nodal and His-Purkinje system than in the ventricle, 
and also in the atrial myocardium (Kanter et al., 1993). Highest levels of Cx40 are found in 
the right atria, followed by the left atria and lower expression levels exist in the ventricles 
(Vozzi et al., 1999). Cx40 forms channels which have higher unitary conductance than Cx43, 
and higher expression levels of Cx40 may contribute to the distinct conduction properties 
of the His-Purkinje system (Beblo et al., 1995; Johnstone et al., 2009; Kanter et al., 1993). 
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Cx45 is also expressed primarily in the conduction system and is found at very low levels in 
the myocardium (Vozzi et al., 1999). 
1.11 Potential signalling pathways for gap junction regulation. 
As regulation of the ventricular gap junction protein Cx43 may play an important role in the 
regulation of CV, recent studies have looked at the way β-AR stimulation may affect Cx43. 
There are multiple ways GJC could be regulated: through an increase in permeability of gap 
junction channels, an accumulation of gap junctions in plaques at the intercalated disc or 
through changes in Cx expression (Giepmans, 2004; Salameh and Dhein, 2011). Regulation 
by cAMP plays a role in the assembly of Cx43 GJs, with the gap junction plaques shown to 
be dynamic structures which increase in size in response to increases in cAMP (Holm et al., 
1999). TenBroek et al. demonstrated that the cAMP analogue, 8-br-cAMP, increased 
assembly of Cx43 gap junctions and that the C-terminal tail of Cx43 was required for the 
reassembly of GJs, with a negative charge on Ser364 improving assembly (TenBroek et al., 
2001). However, as they observed little Cx43 phosphorylation in response to PKA, they 
suggested that increased assembly of Cx43 gap junctions occurs indirectly through a kinase 
pathway other than PKA (TenBroek et al., 2001). This conclusion was supported by a 
subsequent report in which cAMP increased dye-transfer and plaque size in Novikoff 
heptoma cells, but these changes were not seen in the presence of inhibitors of trafficking 
(Paulson et al., 2000a). 
Other studies suggest that regulation of Cx43 is responsible for changes in GJC in response 
to raised cAMP (Salameh and Dhein, 2011). Treatment of neonatal rat cardiac myocytes 
(NRCMs) with isoproteronol (ISO) over 24hrs increased Cx43 expression and subsequently 
increased GJC (Salameh et al., 2006). Transcription of Cx43 in communication deficient cell 
line – the rat Morris hepatoma cell line – is increased ~40 fold in response to cAMP 
elevation (Mehta et al., 1992). Changes in expression are reported to occur after longer 
(24hr) exposures to raised cAMP, which may explain why some studies report no GJC 
response to acute cAMP concentration increases (Kwak et al., 1995; Neyton and 
Trautmann, 1985). It has also been suggested that chronic elevation of cAMP may lead to 
upregulation of MAP kinase (MAPK) pathways, increasing Cx43 expression indirectly 
(Kanter et al., 1993; Saffitz et al., 2000). Conversely, some studies which report increases in 
GJC or CV in response to raised cAMP report no changes in Cx43 expression even after 
prologoned exposure to cAMP (de Boer et al., 2007; TenBroek et al., 2001). 
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There is some conflict as to whether cAMP and β-AR mediate acute changes via 
permeability and assembly of gap junctions, or slower changes through the upregulation of 
gap junction expression. It is possible that both possibilities could occur via distinct cAMP-
mediated signaling pathways. Somekawa et al. measured gap junctional permeability by 
measuring dye-transfer between adjacent cells in neonatal cardiac myocytes (Somekawa et 
al., 2005). They showed an increase in dye-transfer in response to increased cAMP, 
accompanied by both increased accumulation of Cx at the intercalated discs and an 
increase in the size of gap junction plaques. Activation of PKA by the PKA specific activator 
N6-benzoyladenosine-3′,5′-cyclic monophosphate (6Bnz) also led to an increase in dye 
transfer between cells, but with little change in levels of Cx at the intercalated discs. An 
alternative to the classical PKA pathway is cAMP mediated activation of Epac. The Epac 
specific activator 8-(4-chlorophenylthio)-2′-O-methyladenosine-3′,5′-cyclic monophosphate 
(8CPT) led to an increase in dye transfer through increased accumulation of Cx at the 
intercalated discs (Somekawa et al., 2005). This suggests that cAMP can regulate GJC 
through both PKA and Epac dependent pathways. 
In summary, there is considerable evidence that connexin function can be altered by β-AR 
stimulation and raised intracellular cAMP, both in the short-term (via phosphorylation or 
connexin assembly) or long-term (via altered turnover or expression). The majority of these 
reports use neonatal cardiac preparations to facilitate studies of intracellular pathways and 
few studies examine the functional consequences in terms of CV or electrophysiological 
characteristics. Therefore, the role of these pathways in the acute effects of β-AR 
stimulation on CV in the adult heart remains uncertain. 
1.12 The interaction between conduction velocity and action 
potential duration to cause re-entrant arrhythmias. 
APD and CV are important parameters in determining the propensity to re-entrant 
arrhythmias in the mammalian heart. Under normoxic conditions, the APD is the main 
determinant of the effective refractory period (ERP) i.e. the time limit after which an area 
of myocardium can be re-excited. This period multiplied by the CV gives a measure of the 
electrical “wavelength” of the myocardium. This concept, originating approximately 100 
years ago was used to predict the likelihood of re-entrant arrhythmias, i.e. the smaller the 
electrical wavelength, the more likely that re-entrant arrhythmias would occur within a 
fixed geometry. Since then several studies have indicated that electrical wavelength is a 
good predictor of propensity to tachy-arrhythmias (Weiss et al., 2000). In the case of 
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increased sympathetic nervous system activity, the shortened AP and ERP would be pro-
arrhythmic unless there was a commensurate increase in CV. However, the extent to which 
mediated changes in CV are able to stabilise ventricular electrophysiology in either atrial or 
ventricular tissue is at present unclear.  
Increased sympathetic activity may also modulate arrhythmic activity in the heart by 
altering the frequency of triggered activity, i.e. non-sinus spontaneous depolarisation in 
either the atria or ventricle which can initiate sustained arrhythmic activity. Early studies 
suggest that sympathetic activity increases the frequency of triggered activity, making the 
occurrence of arrhythmias more likely (Han et al., 1964). Thus, the effect of increased 
sympathetic activity on the vulnerability of the heart to arrhythmic activity is complex. 
1.13 Changes in ventricular conduction in cardiac disease 
Poor contractility and susceptibly to arrhythmias characterises heart disease from a variety 
of different causes. Uncoupling of GJs occurs acutely in ischaemic myocardium and 
profoundly slows conduction into an ischaemic area (Kléber et al., 1987; Severs et al., 
2004). In the surviving myocardium, over longer time periods, gap junctions remodel during 
heart failure in humans (Severa et al., 2004; Smith et al., 1991) and in animal models of 
cardiac disease (Matsushita et al., 1999; Smith et al., 1991). Cx43 expression is reduced 
(Wang and Gerdes, 1999) causing both an overall slowing and increased heterogeneity of 
CV (Kojodjojo et al., 2006; Peters, 2006). There is also an increased lateralisation of Cx43 in 
cells at the epicardial border zone (EBZ) of infarcts in canine hearts (Peters et al., 1997). 
Some studies suggest transverse coupling is decreased to a greater extent than longitudinal 
coupling in infarcted hearts (Cabo et al., 2006; Yao et al., 2003). It also suggests that Cx43 
which has relocalised to lateral membranes may not form functional gap junctions (Cabo et 
al., 2006). Additionally, reduced Na current also occurs in heart disease and would also 
contribute to a slowing of CV (Lue and Boyden, 1992; Pu et al., 1998). In inducible models 
of ischemia, Cx43 redistribution to lateral regions plays a significant role in post-ischemic 
arrhythmias, facilitated through reduction in PKC-epsilon phosphorylation of Cx43 (O’Quinn 
et al., 2011). Experimentally increasing phosphorylation of Cx43 at PKC sites (Cx43-S368) in 
mouse hearts reduces lateralisation and can limit post-infarct arrhythmias (Jozwiak and 
Dhein, 2008; O’Quinn et al., 2011). 
Changes in β-AR signalling are also known to occur in heart failure, typically down-
regulation of β1-ARs (to ~50% of control) occurs in response to a chronic increased activity 
of sympathetic nerves that normally occurs post myocardial infarction (Lohse et al., 2003a). 
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The proportion of β1:β2 changes to ~50:50 and there is recent evidence in a rat HF model 
for the loss of the selective of expression β2-ARs in the T-tubular network and subsequent 
loss of localised cAMP production on selective β2-AR stimulation (Nikolaev et al., 2010). 
Other aspects of the adrenoceptor pathway are altered in hypertrophic myocardium, 
including the uncoupling of the remaining receptors from Gs via increased activity of β-AR 
kinases (Lohse et al., 2003a). Changes in β-AR signalling in heart failure could reduce 
adrenergic regulation of INa and/or Cx43 which may attenuate the normal increase in CV 
that accompanies increase in heart rate. Potentially the limited CV response may affect 
both the inotropic response and contribute to the generation of arrhythmias. 
1.13.2 Cardiac arrhythmias 
Normal electrical conduction in the heart involves an AP originating from the sino-atrial 
(SA) node, conducted through the atria via the atrio-ventricular (AV) node down to the 
Purkinje fibres and then to the ventricles. Abnormality in the properties of ionic currents 
can lead to abnormal impulse generation and/or propagation which further leads to 
electrical disorder in the ventricles. This thesis will focus on the mechanism of arrhythmia 
generation termed re-entry, as alterations in CV can lead to the generation of re-entry 
arrhythmias. 
Re-entry  
Re-entry is the circulation of the cardiac impulse causing repetitive excitation of the heart. 
It depends upon the occurrence of unidirectional block, causing activation to occur in one 
direction only. For the arrhythmia to be maintainted, the size of the circuit must exceed the 
recovery period of the tissue within the circuit. Features which contribute to this are: a 
large circuit, slow CV or a short effective refractory period (ERP) (Jalife et al., 2009). This 
can be summarized by the 'wavelength’ theory. CV x ERP is defined as the cardiac 
wavelength. A lower wavelength promotes the generation and maintenance of re-entrant 
circuit arrhythmias, due to slow CV or a shorter ERP. Therefore, a lower CV could contribute 
to arrhythmogenesis and in principle, a higher CV could be anti-arrhythmic. 
Uncoupling of GJs has been demonstrated to occur in ischaemic regions of the heart 
(Kléber et al., 1987), which profoundly reduces CV. In surviving regions of the heart, 
remodeling of gap junctions has been shown to occur in heart failure in humans (Severs et 
al., 2004; J. Smith et al., 1991) and in animal models (Matsushita et al., 1999). Alongside 
this, β-AR signaling, particular β1ARs, has also been demonstrated to be down-regulated in 
heart failure (Lohse et al., 2003a; Nikolaev et al., 2010). Therefore, understanding the 
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regulation of CV by β-AR stimulation in heart failure could be key to understanding the 
changes in disease which lead to the generation of arrhythmias. 
1.14 Hypothesis and Aims  
Ventricular CV depends on multiple factors, including tissue excitability and intercellular 
resistance, both of which are potentially modifiable via β-AR stimulation. Despite the key 
role of ventricular CV in the electrical stability of the mammalian heart, little is known of 
how it is influenced by the activity of the autonomic nervous system. This introduction has 
focused on the literature associated with the potential for β-AR stimulation to modulate 
CV. In vivo and in vitro studies on whole hearts suggest that sympathetic nerve stimulation 
increases ventricular CV, but there is uncertainty over the magnitude of this response and 
little data that would allow the electrophysiological mechanism to be distinguished. In vitro 
studies on isolated cardiac muscle preparations report increases in GJC in response to β-AR 
stimulation or increasing intracellular cAMP, but the intracellular mechanisms are still 
unclear to explain both rapid (within 1 minute) or more long term (within several hours) 
effects on gap junction function. An additional issue is that many of these latter studies are 
carried out in neonatal cardiac myocytes in which the localisation of Cx is very different to 
that in adult ventricular myocytes. 
Hypotheses: 
i) An increase in ventricular CV is a component of the adrenergic response 
ii) This increase in CV is mediated by changes in gap junctional conductance 
iii) Increased CV in response to adrenergic stimulation is mediated via β-1 
adrenergic receptors 
iv) Ventricular CV is increased by raised cAMP via a PKA-dependent mechanism 
The overall aim of this PhD was to measure and quantify the effects of β-AR activation on 
CV and determine the relative contribution of changes in AP rise time and intercellular 
resistance to the response in adult ventricle. 
The individual aims of the project were: 
i) To develop a method by which CV can be measured in the intact rat ventricular 
myocardium on a scale which is primarily influenced by changes in cell-cell 
communication 
ii) To determine if β-AR stimulation altered CV in the intact rat heart and to 
determine if this was a cAMP mediated response 
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iii) To develop a method by which APs and Ca2+ transients can be simultaneously 
measured from the site at which CV is recorded using fluorescent dyes, Di-4-
ANEPPS and Fura-4-AM 
iv) To record the effect of β-AR stimulation on the ventricular AP and Ca2+ 
transient over the same time course as the CV response and determine if 
changes in cardiac electrophysiology cause the change in CV 
v) To examine the effect of Ca2+ on CV by altering extracellular Ca2+ and using the 
L-type Ca2+ channel inhibitor, Nifedipine 
vi) To investigate the signalling pathway responsible for the change in CV via 
inhibitor studies 
vii) To determine if a change in CV in response to β-AR stimulation is primarily 
mediated by gap junctions 
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2. General Methods 
2.1 Modified Tyrode’s Solution 
93mM NaCl, 20mM NaHCO3, 1mM Na2HPO4, 1mM MgSO4.7H2O, 5mM KCl, 20mM Na+ 
acetate, 25mM glucose. Solution contained 1.8mM CaCl2 unless otherwise stated. The 
solution was filtered through a 5µm filter (Millipore) and continuously bubbled with a 
gaseous mixture containing 95% O2 and 5% CO2 to maintain pH 7.4 
2.2 Preparation: Langendorff perfused rat heart 
Adult, male Wistar Han rats (Envigo, UK) were used in these experiments. These rats were 
weight-matched at 250-300g. All procedures were carried out in accordance with the 
Animals Scientific Procedures Act (ASPA, 1986). Rats were euthanized by cervical 
dislocation and the hearts excised and placed in chilled modified Tyrode’s solution. The 
hearts were Langendorff perfused with oxygenated modified Tyrode’s solution gassed with 
95% oxygen and 5% CO2 to maintain oxygenation and pH7.4. Hearts were perfused at a 
constant flow rate – rather than constant pressure – of 12ml/min using a peristaltic pump. 
Pressure was continually monitored using an inline pressure monitor, and typical pressure 
readings were between 40-60mmHg.  The perfusate was maintained at a temperature of 
37°C. 
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Fig. 2.2.1 Diagram of the Langendorff setup 
Oxygenated Tyrode's was retrogradely perfused through the rat aorta and then to the coronary 
arteries. A peristaltic pump was used to keep the flow of Tyrode's at a constant rate. A bubble trap 
and heat exchange coil protected the heart from air bubbles - which would block the blood vessels of 
the heart - and kept the Tyrode's solution at 37°C at the point it reached the heart. The heart was 
cannulated and suspended from the aorta, allowing it to contract freely. A pressure transducer was 
used to record the pressure in the system. 
2.3 Conduction Velocity Recordings 
Electrode Design and Analysis 
Measurements were taken using custom electrodes, consisting of silver bipolar stimulating 
electrodes and two sets of silver bipolar recording electrodes in fixed positions. Channel 1 
(Ch1) recording electrodes were positioned a fixed distance apart from Channel 2 (Ch2) 
recording electrodes and set in epoxy. These electrodes were placed flat against the 
epicardium of the LV (Fig. 2.3.1A). CV was recorded by pacing continuously on the 
epicardium at a fixed interval and recording the signals from the Ch1 and Ch2 recording 
electrodes continuously at a sampling rate of 20kHz. The difference in time between the 
peaks on the Ch1 and Ch2 electrodes was taken as the difference in time between 
activation of the LV at each pair of electrodes. As the distance between these electrodes 
was known, CV could be calculated using CV=Distance/time. Heart rate was recorded in 
unpaced hearts by measuring the time difference between peaks on a single channel. 
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Recordings were made using software written in house: ACQ1 (Dr. Francis Burton, 
University of Glasgow). 
Fig. 2.3.1 Electrode Design. 
 A) Photo of setup showing positioning of the electrode on the surface of the LV. B) Diagram of 
electrode design, showing the stimulating electrodes and two sets of recording electrodes which are 
all set in epoxy. Xmm is the distance between electrode pairs and is between 1 and 1.6mm, as several 
different electrodes were made and used during these experiments. C)  Example traces taken from an 
experiment showing the stimulus artefact and the peaks on the Ch1 and Ch2 recording electrodes.  
Traces were analysed using a program written in house (Dr. Francis Burton, University of 
Glasgow) in MATLAB (Mathworks). The software detects the peaks in the traces and 
calculates the delay between each pair of peaks, creating a continuous trace of the 
conduction delay (Fig. 2.3.2). This allows detection of small changes in CV and shows the 
exact time point at which these changes occur. Our system was limited to a digitization rate 
of 20kHz – this limited the resolution of the conduction delay (Fig. 2.3.2 B), producing a 
trace which fluctuates between two values when in reality the actual value will lie between 
the two recorded delays. Adjacent averaging of 30 sequential points of the conduction 
delay traces was used to minimise the impact of this. 
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Fig. 2.3.2 Analysis Program 
A) Example trace from section of experiment. Program detects trace peaks (black +) from the Ch1 
and Ch2 electrodes. This allows a continuous conduction delay (ms) to be calculated B). Note the 
digitisation rate (20KHz) limits the resolution of the conduction delay (0.05ms) and the subsequent 
CV calculation. 
 
Fibre Orientation 
Position of the electrode relative to fibre orientation leads to differences in conduction 
velocity: CV is roughly twice the CV in the longitudinal orientation (parallel to the fibre 
orientation) than in the transverse orientation (perpendicular to fibre orientation). To 
confirm that we were able to detect changes in CV relative to fibre orientation, the 
electrodes were rotated through 360⁰ with CV recorded at 30⁰ intervals. As it was not 
possible in this setup to identify fibre orientation, longitudinal CV was estimated by 
rotating the electrode until the fastest CV was observed: this was termed longitudinal CV. 
The electrode was then rotated 90⁰ to record transverse CV. This was termed 0⁰ for the 
diagram shown below (Fig. 2.3.3). From the 0⁰ point, the electrode was rotated in a 
clockwise direction and an individual CV recording was made at each 30⁰ interval. CV was 
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found to be approximately 50% faster at 90⁰ vs. 0⁰, representative of the difference 
between longitudinal and transverse CV due to fibre orientation.  
 
Fig. 2.3.3 360⁰ recording of CV on the rat LV.  
A) Diagram showing the angle of the electrodes and the direction of propagation at 0⁰ and 90⁰. B) 
Range of CVs recorded from 3 rats across 360⁰ shown as a % of the max CV recorded. 
To minimize variation in CV between different hearts, CV was recorded at as close to 
longitudinal CV as possible. At the beginning of each CV experiment, the electrodes are 
rotated through various angles to locate the fastest CV (minimum conduction delay). 
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2.4 Microelectrode Recordings 
Sharp microelectrode (ME) measurement of Vm is the ‘gold standard’ method by which 
intracellular APs are recorded. APs were measured from epicardial myocytes of the LV at 
the same region as CV recordings in previous experiments. This allowed us to measure the 
effect of β-AR stimulation on the AP to ascertain if changes in cellular electrophysiology 
could explain recorded changes in CV. 
ME AP recordings were carried out on horizontal Langendorff, with the heart positioned so 
that the LV surface faced up. Preparations were submerged in a specially designed Perspex 
water bath maintained at 37oC, containing modified Tyrode’s solution (see 2.1). Sharp glass 
microelectrodes of between 40-50MΩ were pulled (Flaming/Brown Pipette 97 
Micropipette Puller Sutter Instruments, Novato, CA) and filled with 1M KCl. Silver Chloride 
(AgCl) wire was used in the micropipettes – the Ag wire was galvanically chlorided in lab. 
The potential difference between the microelectrode and a Ag/AgCl reference electrode 
(commertially bought) placed in the water bath was recorded. ME recordings measured 
using an Axoclmap 2B amplifier and digitally recorded at 28kHz. A HS2A headstage (10x 
gain) with an input impedence of 500MΩ was used.  An ECG was recorded using Ag/AgCl 
disc electrodes and AP recordings were made using WinEDR (Dr John Dempster, University 
of Strathclyde, UK).  The heart was LV paced using bipolar platinum electrodes. 
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Fig. 2.4.1 Diagram of ME setup. 
Potential difference between the glass microelectrode and the waterbath reference electrode were 
recorded using WinEDR (Dr John Dempster, University of Strathclyde, UK). 
 
2.5 Optrode recordings 
Although ME recordings allowed us to record APs from the site at which we recorded CV, it 
was not possible to record CV and AP measurements simultaneously on this setup. Also, to 
obtain a continuous ME recording of APs was technically challenging, even in a 
mechanically quiescent heart. Therefore, a system was designed which allowed the 
simultaneous recording of CV, optical APs and optical Ca2+ transients from the same site on 
the LV. Electrodes with a similar design as previous setups (Fig. 2.3.1 B) were set into the 
centre of a fibre optic lightguide, which allowed the transmission and collection of light 
from sites directly adjacent to the CV recording electrodes (Fig. 2.5.1 A). The fibres of the 
fibre optic light guide were fixed in place in crescent shapes to either side of the CV 
recording electrodes, which each side containing five individual fibre optic fibres; this 
covered two areas of 4mm by 2mm which were 4mm apart. 
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Fluorescence was recorded simultaneously at 2 wavelengths (550nm and 650nm) using 
photomultiplier tubes (PMTs) to allow ratiometric measurements of voltage using Di-4-
ANEPPS. The 470nm LED was switched on for 5s at a time every 30s. This recorded a train 
of 60 APs, which would later be averaged during the analysis process to give a mean AP 
from this time-point. 
 
 
Fig. 2.5.1 Diagram of optrode setup. 
A) The 'optrode' incorporates the CV electrodes from the previous setup and includes a fibre optic 
lightguide which allows the excitation of fluorescent dyes and collection of light from the heart. B) 
CV recordings can be made in the same way as shown in section 2.2. C) An example averaged AP 
taken from recordings made using the optrode and the voltage-sensitive dye, Di-4-ANEPPS. D) An 
example averaged Ca2+ transient recorded with the optrode and the Ca2+ sensitive dye, Fura-4.2.5.1 
Voltage Sensitive Dye: Di-4-ANEPPS 
 
To record APs using the optrode, voltage sensitive dyes were used. These are dyes which 
respond rapidly to changes in membrane potential, which alters their fluorescence; this 
change is extremely fast and allows the recording of changes in electrical potential within 
milliseconds. 
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Fig. 2.5.2: Diagram of optrode light path 
Diagram showing the set-up for the optrode recordings. LP = long pass filter. LED = light emitting 
diode. Light from the LEDs would pass through a series of long pass filters to reach the fibre optic 
light-guide which would shine light on to the heart. Emission from the flouroescent dyes would be 
collected by the light-guide and pass through the LP500 filter to the PMTs. There the LP535 filter 
would split the emission between the 550nm and 650nm PMTs. 
The dye used in this study is Di-4-ANEPPS (Biotium, UK), an ANEP ratiometric dye. Di-4-
ANEPPS is not fluorescent until membrane bound, but when in the membrane its peak 
excitation wavelength is 470nm and its peak emission is at 600nm (Fig 2.5.2 A). Fig. 2.5.2 B 
shows the Di-4-ANEPPS emission spectrum in an adult rabbit cardiac myocytes. The black 
line shows emission of the dye in normal Tyrode's and the red dotted line shows emission 
in high potassium (K+), which depolarises the cardiac cell membrane. The change in 
membrane potential caused by the high K+ causes a spectral shift in fluorescence: this 
spectral shift is extremely small and can be seen more clearly in Fig. 2.5.2 C. 
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Fig. 2.5.2 B shows the relative change in fluorescence of Di-4-ANEPPS in normal Tyrode's 
and Tyrode's containing high K+.  The change in fluorescence peaks at two different 
wavelengths. Emission was split and recorded on two separate PMTs set to 550nm and 
650nm, which made it possible to take a ratio of the fluorescence at each wavelength. 
Calculating the ratio helps reduce the artifact associated with movement during the 
recording.  Di-4-ANEPPS bleaches in the presence of light – i.e. the fluorescence of the dye 
decreases with the time exposed to excitation light. As the emitted fluorescence recorded 
on at the two channels will decrease to the same relative extent due to bleaching, taking a 
ratio also reduces the effect of bleaching on the signal level. 
50μL Di-4-ANEPPS (2mM stock concentration) was diluted in 2ml of modified Tyrode’s 
(50µM) and added slowly as a bolus over 10s, using a syringe cannula as close to the heart 
as possible (Fig. 2.7.1). Due to the flow-rate of 12ml/min, this equated to an approximate 
concentration at the heart of 25µM. This method of Di-4-ANEPPS administration had been 
optimized in previous work carried out in the lab.  A light-emitting diode (LED) that emitted 
light at 470nm was used to excite the dye. To minimize the effect of bleaching, the 470nm 
LED was turned on at either 30s or 1min intervals throughout these experiments for 5s at a 
time to record a train of APs that were subsequently averaged prior to analysis. 
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Fig 2.4.1.1 Excitation and Emission spectra of Di-4-ANEPPS (Recorded by Dr. Ole Kemi and Dr. Niall 
MacQuaide, University of Glasgow). 
A) Excitation and emission spectra of Di-4-ANEPPS. Peak excitation occurs at 473nm wavelength and 
peak emission is recorded at 607nm. B) Emission spectra of Di-4-ANEPPS in rabbit cardiac myocyte in 
presence and absence of high K+. High K+ depolarises the cell membrane and causes a spectral shift in 
Di-4-ANEPPS fluorescence. C) The spectral shift of Di-4-ANEPPS is shown; from this it is possible to see 
that there is a larger change in fluorescence at two wavelengths. By recording at both these 
wavelengths, a ratio can be taken. 
2.5.2 Ca2+ Sensitive Dye: Fura-4-AM 
Fura dyes are calcium sensitive dyes used for measuring intracellular Ca2+ concentrations. 
They are aminopolycarboxylic acids which bind to free Ca2+ in the cytoplasm (Grynkiewicz 
et al., 1985). Fura-4 is a lower affinity version of Fura-2, with a kd of 800nM: although this 
means there is a lower sensitivity to diastolic levels of Ca2+, it allows for better resolution of 
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peak Ca2+ recorded during Ca2+ transients. Fura-4 is designed to be excited sequentially at 
340nm and 380nm, with emission from both being collected at 510nm. This allows for a 
ratiometric measurement to be taken as a result of the emitted fluorescence from the two 
excitation wavelengths. However, using an LED based system does not easily allow 
excitation at 340nm since current LEDs that emit at this wavelength are of very low power. 
Therefore in these studies, Fura-4 was excited with a 360nm light from a longer wavelength 
LED. This wavelength is termed the isosbestic point since it represents a Ca2+ insensitive 
sector of the excitation spectrum. This approach still yields a ratiometric measurement of 
Ca2+ since changes in fluorescence signal due to movement or other artefacts are 
minimized due to the fluorescence signal recorded at 360nm.  
 
Fig.2.5.2 Fluorescence excitation spectra of Fura-2 in solutions containing from 0-39.8μM Ca2+ 
(taken from ThermoFisher Scientific). 
Fluorescence excitation of Fura-2 at different concentrations of Ca2+. The excitation of Fura-2 is the 
same as Fura-4; only the Kd of Fura-4 is different. The isosbestic point, at which fluorescence does 
not change in response to Ca2+ concentration, can be clearly seen at 360nm. 
Background recordings of fluorescence were taken before adding Fura-4 to the heart. 
30μM Fura-4-acetoxymethyl ester (Fura-4-AM, Molecular Probes, Life Sciences, UK) - a cell 
permeable form of Fura-4 - was perfused into the heart over 5min: this was done at half 
the normal perfusion rate to allow time for the Fura-4-AM to enter the heart; this also 
allowed us to use smaller volumes of Fura-4-AM. The heart was then left for a further 
10min to allow the acetomethyl groups to be removed by intracellular esterases: this is 
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required for the functioning of Fura-4, but also prevents Fura-4 from diffusing back across 
the membrane. Further to this 2.5mM probenecid (Sigma Aldrich, UK) was perfused on 
with the Tryrode's solution to inhibit anion transport and prevent Fura-4 secretion. 
Recordings were made by exciting with a 360nm optoLED for 5s and then immediately 
switching to a 380nm LED for an additional 5s. Fluorescence was collected at 450nm and 
recorded using the custom software ACQ1 (Dr Francis Burton, University of Glasgow). The 
signals were then background subtracted and ratioed using custom software created in 
house: ViewACQ (Dr. Francis Burton, University of Glasgow). 
The recording of Ca2+ transients alongside APs and CV, using the optrode probe was a new 
technique developed in the lab. Fura-4 concentration, LED power and PMT settings were 
optimized over a series of experiments. Difficulties were encountered due to the low 
power of the 360 LED which generated a signal with low signal:noise. To reduce the impact 
of this noise on the Ca2+ transients, a section of each 360 recording was averaged and this 
average was used to calculate the ratioed Ca2+ transients: i.e. Ca2+ transient ration = mean 
360 / 380 trace.  
2.5.3 Near-simultaneous AP and Ca2+ recordings 
Due to their overlapping emission wavelengths, it was not possible to record both AP and 
Ca2+ signals simultaneously. Instead a protocol was developed which allowed sequential 
measurements of APs and Ca2+ transients. An initial 5s recording was made by switching on 
the 470nm LED: this excited Di-4-ANEPPS and allowed the recording of 5s of APs. The LED 
would then immediately be switched off and the 360nm LED switched on for 5s: this 
allowed the recording of the isbestic point of Fura-4. Finally, the 360 LED would be 
switched off and the 380nm LED would be immediately turned on: this allowed the 
recording of the Ca2+ sensitive portion of Fura-4 emission. Although these recordings were 
not simultaneous, they did allow both APs and Ca2+ transients to be recorded optically in 
the same heart and at the same location on the epicardium. The short time window in 
which these were recorded also allowed comparison of Ca2+ transients and APs at similar 
time-points during drug addition. However, it is important to consider that Ca2+ transients 
were recorded a full 10s after the APs were recorded. 
2.5.4 Analysis 
Both APs and Ca2+ transients were analysed using custom software developed in house: 
RatioAverager (Dr. Francis Burton). Using this program, it was possible to average the 
signals recorded over 5s to a mean single AP or Ca2+ transient. Properties such as the rise 
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time between 10 and 90% of the upstroke (TRise), the amplitude and the duration of the 
transient could be measured. 
2.6 Pacing Protocol 
Bipolar platinum stimulating electrodes were encorportated into the CV electrode design 
(2.3.1B). Bipolar platinum ‘hook’ electrodes were used to pace the heart in ME 
experiments. The heart was paced epicardially on the LV in all experiments. The heart was 
stimulated using a square pulse 2ms in duration. These were generated using an isolated 
constant voltage stimulator (Digitimer, Ltd.) and interval was maintained using a digitimer 
developed in-lab. Threshold for pacing was found by gradually increasing the voltage (V) of 
the pulse until successful pacing of the heart was established. V was mainted at 1.5x 
threshold. Unless otherwise stated, hearts were paced at 8Hz to override the higher 
intrinsic rates seen in adrenergic stimulation. 
2.7 Mechanical Uncoupler 
The normal contraction of the heart can interfere with the recordings. Although it was 
possible to make CV recordings while the heart was contracting, the electrode was more 
likely to be moved by the contracting heart and therefore invalidate the experiment. It is 
also not possible to make optical AP or Ca2+ recordings while the heart is contracting 
normally, as this generates a large motion artifact that is not sufficiently cancelled by 
ratiometric measurements.  
Mechanical couplers act by uncoupling the electrical signal from the physical contraction of 
the myocyte: this leaves the electrical signal unchanged, but prevents the heart from 
contracting during the experiment. Previously used uncouplers include 2,3-butanedione 
monoxime (BDM) and cytochalasin D. However, these uncouplers also have effects on 
intracellular Ca2+ handling, therefore making them imperfect for use in research (Kettlewell 
et al., 2004; Y. Liu et al., 1993).  
A newer mechanical uncoupler, blebbistatin, is believed to have fewer non-specific 
interactions. It is an inhibitor of the ATPases associated with myosin II, and therefore 
prevents the normal cycling of the myosin head and its attachment to actin (Straight et al., 
2003): this prevents cellular contraction. Federov et al. found that blebbistatin at 5-10μM 
eliminated contraction but had no effect on action potential morphology or intracellular 
calcium transients (Fedorov et al., 2007). However, Brack et al. found that blebbistatin at 
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5μM prolonged effective refractory period and caused AP prolongation in the intact rabbit 
heart (Brack et al., 2013a). 
In this study 3μM blebbistatin was used to try to reduce the negative impact of blebbistatin 
on the electrical activity of the heart. It was perfused onto the heart for 25min prior to any 
experimental recordings, so that the heart could reach a steady state. Further to that, all 
control recordings were made in the presence of blebbistatin. All experiments were carried 
out in the presence of 3µM blebbistatin unless otherwise stated. 
2.8 Drug Delivery 
Various drug interventions were used throughout this study. Timing of drug delivery was 
important, so it was necessary that the drug entered the system as close to the heart as 
possible and also that a set drug concentration could be maintained over a chosen period 
of time. To do this, a syringe driver was set up adjacent to the Langendorff system. This was 
set up to perfuse drugs at 0.4ml per min. The syringe cannula passed through the top of the 
rubber bung in the heat exchange coil, down the central channel and the opening was 
positioned immediately before the aortic cannula. This tubing was primed with drug prior 
to the experiment, meaning that as soon as the syringe driver was turned on, drug was 
mixed and delivered directly into the coronary circulation. Passing through the heat 
exchanger ensured that the drug was heated to close to 37⁰C and also allowed the drug to 
mix with the Tyrode's solution prior to reaching the aorta. A second tube through the heat 
exchanger coil was also used to deliver Di-4-ANEPPS to the coronary circulation. 
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Fig. 2.8.1 Diagram of syringe driver and drug delivery. 
Diagram showing the setup of syringe driver used to deliver drugs to the heart. Drugs were perfused 
on at a constant rate, to maintain a constant concentration for the duration of the experiment. A 
syringe cannula was used to ensure that drug was delivered as close to the coronary arteries of the 
heart as possible so that there was minimal 'dead space' in the system. 
2.9 Analysis and Statistics 
AP and Ca2+ transient data were exported from WinEDR (Dr. John Dempster, University of 
Strathclyde, UK) or ACQ1 (Dr. Francis Burton, University of Glasgow, UK) in the acq format. 
The section of trace pertaining to each time point was then exported as a ratio using 
ViewACQ (Dr. Francis Burton, University of Glasgow, UK). In the case of Ca2+ transient 
analysis, a section of the 360 trace (the isobestic point of Fura-4) was averaged, and this 
average was divided by the 380 trace; this reduced signal:noise, as noise was generated on 
the 360nm trace due to the low power of the 360nm LED. The ratioed transients were then 
averaged and analysed using RatioAverager (Dr. Francis Burton, University of Glasgow, UK). 
Example traces were exported using Origin (OriginLab Corporation, USA). 
CV traces were recorded using ACQ1 and exported using ViewACQ. CV analysis was carried 
out using MATLAB (Mathworks, USA) and software generated in-lab. Example traces were 
generated in Origin. 
Graphical and statistical analysis was carried out using GraphPad Prism (GraphPad 
Software, Inc., USA). Unless otherwise stated, graphs are presented as the mean with the 
standard deviation (s.d.) stated in the text. A student’s t-test was used in single comparison 
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tests, whereas a non repeated measures ANOVA with Bonferroni’s post-hoc test was used 
for multiple comparisons. A P-value of <0.05 was considered significant (* = p<0.05; ** = 
p<0.01; *** p<0.001).   
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3. β-adrenergic stimulation increases CV in the intact 
heart 
3.1 Introduction 
The autonomic nervous system (the ANS) is composed of the sympathetic and 
parasympathic branches. The sympathetic nervous system of the heart governs the 'fight or 
flight' response: it allows the heart to rapidly respond to stimuli to increase pump function 
and speed of contraction. The sympathetic nervous system acts through the binding of 
catecholamines to α- and β-adrenoreceptors, though in the normal adult myocardium the 
β-adrenorecptors (β-AR) are the dominant subtype. 
The effect of β-AR stimulation on the heart is well established. β-AR increases heart rate - 
positive chronotropy - via an increase in If - an ion channel directly activated by cAMP 
(DiFrancesco and Tortora, 1991) - and on shortening the conduction delay in the SA (Hutter 
and Trautwein, 1956, 1955; Levick, 2000). β-AR stimulation also causes an increase in the 
force of contraction of the heart - positive inotropy. This is achieved primarily through an 
increase in the inward Ca2+ current and enhancing the intracellular Ca2+ store (Bers, 2001, 
2002); this is dicussed in further detail in 4.1.2. β-AR stimulation also increases the rate at 
which the heart relaxes following contraction - positive lusitropy. This is due to the 
increased uptake of Ca2+ from the cytoplasm by SERCA (Bers, 2002) and also due to an 
increase in the slow outward K+ channel, IKs (Walsh et al., 1988). 
The effect of β-AR on the speed of myocardial conduction however, has not been well 
studied. The majority of studies on the effect of β-AR stimulation on CV were primarily 
carried out in the 1950s and 60s. Initial experiments carried out in in vivo dog hearts 
showed an increase in ventricular CV (Krayer et al., 1951; Siebens et al., 1953) in response 
to epinephrine, however later experiments carried out in the isolated dog heart-lung 
preparations showed only a small and inconsistent increase in CV (Swain and Weidner, 
1957). While Krayer et al. attribute the increase in CV to an increase in serum K+ caused by 
the action of epinephrine on the liver, Wallace and Sarnoff demonstrated that stimulation 
of the left stellate ganglion caused an increase in CV of approximately 6% (Wallace and 
Sarnoff, 1964), suggesting that sympathetic stimulation was having a direct effect on CV in 
the heart. More recent studies on isolated rabbit heart with intact sympathetic innervation 
demonstrate an increase in CV of 30% in response to sympathetic nerve stimulation (Ng et 
al., 2007). However, these studies included conduction via both the ventricle and Purkinje 
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fibres. So, though there is evidence that β-AR stimulation increases myocardial CV, there 
are few studies which measure ventricular CV directly and they do not address the 
mechanism or time-course of this response. 
Using the electrode design shown in Fig. 2.2.3, it was possible to measure conduction delay 
on the epicardial surface over a limited distance (between 1 and 2mm) that ensures only 
local conduction is sampled. Therefore, it was possible to directly record conduction delay 
from myocardial conduction without involving the cardiac conduction system. The initial 
aim of this study was to measure the effect of β-AR stimulation on CV, confirming the 
increase in CV previously recorded and measuring the time-course and amplitude of this 
response. 
The drug used initially to stimulate the β-AR was isoproterenol: ISO is a full agonist of all 4 
types of the β-receptors on the heart. 
This study also aims to determine the signaling pathways responsible for the increase in CV.  
One of the possible second messengers involved in β-receptor signaling in the heart is cyclic 
adenosine monophosphate (cAMP). To ascertain whether this was a cAMP-mediated 
response, drugs which raise cAMP were used: the activator of adenylyl cyclase, forskolin 
(Fsk), and the PDE inhibitor 3-Isobutyl-1-methylxanthine (IBMX) were used to raise 
intracellular cAMP. 
The effect of β-AR on heart rate is previously well documented (DiFrancesco and Tortora, 
1991; Hutter and Trautwein, 1956). In a separate set of experiments, heart rate was also 
recorded to ensure that the dose of ISO used was having the expected effect on the heart, 
to compare the time course of the CV and HR responses and to determine if the heart 
reached a steady state during drug perfusion. 
3.2 Methods 
3.2.1 Drug concentrations 
100nM of isoproterenol hydochloride (ISO) was dissolved in deionoised water (Sigma 
Aldrich, UK). 30μM Fsk and 100μM IBMX (both Sigma Aldrich, UK) were used to achieve a 
near maximal response, based on previous studies (Mehta et al., 1992; Paulson et al., 
2000b; Zhai et al., 2012). Both drugs were dissolved in DMSO. Finally, the combination of 
1μM Fsk and 100μM IBMX was chosen as the combination of drugs to maximally raise 
cAMP in further work:  Fsk gave the most consistent and stable results, however, Fsk is 
known to have some non-specific effects at high concentrations, so the lower 
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concentration of Fsk alongside a PDE inhibitor was chosen as the most effective and 
specific drug intervention. 
All experiments were carried out in the presence of 3µM blebbistatin, unless otherwise 
stated. 
3.2.2 Drug delivery 
Recordings were taken of both heart rate and CV for 5mins prior to drug addition to ensure 
that the heart had reached a steady state and to allow for a control recording. The control 
point for the graphs was taken as 30s prior to drug addition. The drug was perfused on for 
a total of five minutes until the response approached a steady state; in initial experiments 
drugs were added for 3mins (data not shown) but this was not long enough for the 
response to reach a steady state. Recordings continued for 5 minutes following drug 
perfusion to record the 'wash-off' of the response. However, as it appeared the CV 
response had a very slow wash off period, in subsequent experiments the wash-out period 
was not recorded. 
In the protocol to determine the ISO dose response curve, CV was taken as the maximal CV 
response. Each concentration was recorded separately on different hearts, as prolonged 
exposure to ISO may induce a desensitization response which would reduce the heart's 
response to ISO. 
3.2.3 Heart Rate Recordings 
Interval was recorded continuously throughout the experiment using the same electrodes 
as used for the CV recordings:Interval was recorded as the time between peaks on a single 
channel - the trace recorded from a single pair of electrodes. Heart rate was calculated 
from interval as beats per minute. 
3.2.4 Conduction Velocity Recordings 
Conduction delay was recorded continuously through the experiment, as described in the 
methods (Fig. 2.2.1; Fig. 2.2.2) and CV was calculated from the conduction delay (v=d/t). 
The heart was paced continuously at 130ms (approx. 8Hz) to prevent the increase in 
intrinsic HR caused by β-AR stimulation from disrupting pacing. The heart was paced on the 
epicardium of the left ventricle. 
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Results 
3.3 CV response to IBMX in presence and absence of blebbistatin 
The mechanical uncoupler blebbistatin was used to uncouple the electrical activity from 
the contraction of the heart in all CV experiments. This means that the heart remains still 
during recordings, which allows for more reliable and consistent CV recordings and is also 
required for the AP and Ca2+ recordings carried out in later experiments. 
As it was possible to make CV recordings without the use of a mechanical uncoupler, the CV 
response to IBMX was recorded both in the presence and absence of blebbistatin to ensure 
that blebbistatin was not having a non-specific effect on CV. 
100μM IBMX increased CV 11.5±2.5% in the absence of blebbistatin (p<0.05, n=3) and by 
9±1.9% in the presence of blebbistatin (p<0.05, n=4). The difference between the 
responses in the presence and absence of blebbistatin was not significant (Fig 3.3.1). 
 
Fig. 3.5.1 There is no significant difference between the CV response to IBMX in the presence and 
absence of 3μM blebbistatin.  
White bar indicates DMSO control, black represents treatment with 100μM IBMX in the absence of 
blebbistatin and grey shows hearts treated with 100μM IBMX while also continuously perfused with 
3μM blebbistatin. CV was taken as the max response to IBMX.  IBMX significantly increased CV in the 
presence and absence of blebbistatin (p<0.05, n=4). Data are shown as mean±s.d.  There was no 
significant difference between the IBMX response in the presence and absence of blebbistatin. 
(*=p<0.05) 
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3.4 The β-receptor Agonist ISO Increases Left Ventricular 
Conduction Velocity in the Intact Rat Heart 
HR was measured continuously as 100nM ISO was perfused onto the heart. ISO caused a 
rapid increased in mean HR from 270±50bpm to 360±80bpm (Fig 3.4.1 C). Mean heart rate 
in the control was recorded as 250±30bpm.  Due to the high degree in variation in heart 
rate between individual hearts, % change in heart rate was calculated. The max response of 
HR to ISO was on average a 30±20% (p<0.05 n=4) above control values. There was no 
significant change in the time control (Fig. 3.4.1 E). Following drug perfusion, the heart rate 
response began to wash out within five minutes, returning to 6±14% above the control 
heart rate recording. 
Left ventricular CV increased in response to treatment with 100nM ISO: CV increased from 
72±9cm/s to 78±10cm/s at its highest point (Fig. 3.4.1 D). The response was slow, with 
highest CV recorded after perfusion with ISO had stopped. The time control fluctuated 
between 66±10cm/s and 68±10 cm/s. This was probably due in part to limitations with the 
digitisation rate, as described in Fig. 2.2.2.  Again, due to the high degree of variation in CV 
between different hearts, % change in CV was calculated. A change in CV - at its highest 
point - of 8±4% was recorded (p<0.01, n=4). No significant change was recorded in the time 
control (Fig. 3.4.1 F). This is in line with previous experiments looking at the effect of 
sympathetic stimulation on CV (Wallace and Sarnoff, 1964) but demonstrate that the 
increase in CV is due to changes in myocardial CV and not other segments of the 
conducting system. The CV response to ISO did not return to normal within the 5min 
washout period: CV remained at 7±4% above control recordings at the end of the 
experiment. 
A dose response to ISO was carried out to ensure that the maximal response to ISO was 
being recorded. Concentrations between 0.1nM and 100nM were used. A near maximal 
response was recorded at 10nM: ~11.3±1.7cm/s at 10nM (SEM, n=4), vs. 11.8±1.4cm/s at 
100nM (SEM, n=5), so higher concentrations of ISO were not used (Fig. 3.4.2). 
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Fig 3.4.1 Effect of 100nM isoproterenol (ISO) on heart rate (HR) and CV in the intact rat heart 
Time control is shown in black and the ISO trace in grey. Black bar and dotted lines indicate time over 
which ISO was perfused onto the heart. Data shown is mean at individual time points. A) Example 
traces showing the effect of ISO on HR. B) Example traces showing the effect of ISO on CV. C) Average 
HR response to ISO. Error bars represents SE. D) Average CV response to ISO (n=4). E) %Δ in HR in 
response to ISO. Increase in HR in response to ISO became significant (p<0.05, n=4) at 120s. At 300s 
the change was no longer significant (n=4). F) %Δ in CV in response to ISO. Increase in CV became 
significant at 210s (p<0.05, n=4). At 330s-600s p<0.01 (n=4). 
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Fig 3.3.2 Dose response of CV to ISO. 
Graph showing the dose response of CV to ISO. Data displayed as mean with bars to represent 
standard error (SEM). ISO was perfused on over 5 minutes and the peak CV recorded during that time 
was recorded as the CV response at that concentration. n=4 at Control, 1x10-10, and 3x10-10. n=2 at 
1x10-9. n=5 at 1x10-7M. 
3.5 Treatment with Forskolin and IBMX Increases Left Ventricular 
CV in the Intact Rat Heart 
30μM Fsk caused a rapid increase in HR in the intact rat heart: heart rate was increased 
from 280±200bpm to 420±30bpm (Fig. 3.5.1 C). Fig. 4.4.1E shows an increase in HR of 
50±20% at its highest point (p<0.001, n=4). There was no significant change in the DMSO 
control. Fsk did not appear to wash out, with heart rate remaining at 30±7% above the 
resting heart rate at the end of the 5min washout period. 
30μM Fsk increased left ventricular CV: CV increased from 75±8cm/s to 85±11cm/s (Fig. 
3.5.1 D). This was a change of 13±2% (Fig. 3.5.1 F) and was significantly different from the 
DMSO control (p<0.001, n=4). There was no significant change in the DMSO control. Again, 
the CV response did not return to normal within the washout period, with CV remaining at 
9±6% higher than the control. However, this results was no longer significant when 
compared to the DMSO control (n=4), suggesting a high degree of variability. 
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Fig 3.5.1 Effect of 30μM forskolin (Fsk) on heart rate (HR) and CV in the intact rat heart. 
Black bar and dotted lines indicate time over which Fsk was perfused into the heart. Data are shown 
as mean at individual time points. A) example traces showing the effect of Fsk on HR. B) example 
traces showing the effect of Fsk on CV. C) Average HR response to Fsk. Error bars represents SE.(n=4) 
D) Average CV response to Fsk (n=4). E) %Δ in HR in response to Fsk. Increase in HR in response to Fsk 
became significant (p<0.05) at 90s (n=4). At 120s-570s p<0.001. F) The %Δ in CV in response to Fsk. 
Increase in CV became significant at 210s (p<0.01). At 330s-540s p<0.001 (n=4). 
These results show the raising cAMP, independent of β-AR stimulation, increases CV in the 
intact rat heart. 
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Fig 3.5.2 Effect of 100μM 3-Isobutyl-1-methylxanthine (IBMX) on HR and CV in the intact rat heart.  
Black bar and dotted lines indicate time over which IBMX was perfused into the heart. Data are 
shown as mean at individual time points. A) example traces showing the effect of IBMX on HR. B) 
example traces showing the effect of IBMX on CV. C) Average HR response to IBMX. Error bars 
represents SE.(n=4) D) Average CV response to IBMX (n=6). E) %Δ in HR in response to IBMX. Increase 
in HR in response to IBMX became significant (p<0.05) at 240s-300s (n=4). F) %Δ in CV in response to 
IBMX. Increase in CV became significant at 270s-450s (p<0.05, n=6). 
The PDE inhibitor IBMX was used to confirm this result by raising cAMP in an independent 
fashion. IBMX is a global inhibitor of PDEs, which breakdown cAMP, and therefore 
inhibiting PDEs increases intracellular cAMP. 
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100μM IBMX increased HR from 260±80bpm to 390±200bpm (Fig. 3.5.2 C), which was an 
increase of 60±40% (Fig. 3.5.2 E).  This increase was significant when compared to the 
DMSO control (p<0.05, n=4).  Heart rate began to return to normal after perfusion of IBMX 
ceased, with heart rate returning to 16±7% above control within the five minute washout 
period. 
Treatment with IBMX increased left ventricular CV in the intact heart. IBMX increased CV 
from 69±4cm/s to74±6cm/s (Fig. 3.5.2 D). Fig 3.4.2 F shows a maximal increase in CV of 
9±4%, which was significant when compared to the DMSO control (p<0.001, n=4). CV began 
to decrease towards control values during the washout period: at the end of the five 
minutes, CV was 5±3% above control values. This was not significantly different from the 
DMSO control (n=4), suggesting a high degree of variability in both the control and the 
IBMX trace at this time-point. 
These results confirm the Fsk results and show that raising cAMP increases LV CV in the rat 
heart. 
Finally, a combination of a lower dose of Fsk with IBMX was used to raise cAMP (Fig. 3.5.3). 
1μM Fsk and 100μM IBMX were perfused at the same time onto the heart for 5min. As the 
heart rate response for IBMX and Fsk had already been recorded, only CV was recorded for 
these experiments. Washout was also not recorded during these experiments. 
Treatment with Fsk and IBMX raised CV from 61±7cm/s to 67±6cm/s (Fig. 3.5.3 B). This was 
an increase of ~9±1% at its highest point and was significant when compared to the DMSO 
control (p<0.001, n=4). 
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Fig 3.5.3 Effect of 1μM forskolin (Fsk) + 100μM 3-Isobutyl-1-methylxanthine (IBMX) on CV in the 
intact rat heart. 
Black bar and dotted lines indicate time over which Fsk+IBMX was perfused into the heart. Fsk+IBMX 
was perfused on for five minutes. Data are shown as mean at individual time points. A) Example 
traces showing the effect of Fsk+IBMX on CV. B) Average CV response to Fsk+IBMX. Error bars 
represents SE.(n=4) C) %Δ in CV in response to Fsk. Increase in CV became significant at 150s (p<0.01, 
n=4). 180s-300s p<0.001. 
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3.6 Discussion 
3.6.1 Summary 
Previous studies looking at the effect of β-AR stimulation on myocardial activation time had 
reported a decreased ventricular conduction time in response to epinephrine (Krayer et al., 
1951; Siebens et al., 1953; Swain and Weidner, 1957; Wallace and Sarnoff, 1964). These 
studies date from the 50s and 60s, and did not distinguish between changes in Purkinje 
fibre conduction or myocardial CV (Mendez et al., 1964; Swain and Weidner, 1957). Neither 
did they investigate the signaling pathways involved in these changes. 
More recent studies have looked at the effect of raising cAMP on cell-cell conduction and 
intercellular resistance (Burt and Spray, 1988; Darrow et al., 1996; Somekawa et al., 2005). 
These studies have found that increasing cAMP can decrease intracellular resistance and 
suggest that these changes are gap junction mediated (Darrow et al., 1996; Somekawa et 
al., 2005). However, these studies were carried out in cell pairs or cultured cell lines and 
therefore cannot directly address the effect on CV. 
This study has found that stimulation of β-AR with the non-specific β-agonist ISO increases 
CV in the intact heart. As the heart was paced on the epicardium within 1.6mm of the 
recording electrodes, it is assumed that this corresponds with an increase in myocardiul CV 
independent of the His-Purkinje system. This study also showed that raising cAMP, one of 
the second messengers of β-AR signaling, also increases CV. Raising cAMP was achieved by 
manipulating two distinct pathways; increasing cAMP synthesis and decreasing cAMP 
degradation, respectively. The results indicate that the change in CV is not due to non-
specific effects of the drugs or due to effects specific to either adenylyl cyclase or PDEs. 
3.6.2 Relevance To Heart Failure 
The effect of β-AR stimulation on the heart has been extensively studied: particularly its 
effect on heart rate, force of contraction (positive inotropy) and on the speed of relaxation 
(positive lusitropy) (Hicks et al., 1979; Lehnart and Marks, 2007; Marx et al., 2000; Yue et 
al., 1990). Its effects on the heart are diverse and involve a range of secondary messengers 
(Hayes et al., 1979). Understanding not only the effect of β-AR stimulation on the heart, but 
also which intracellular pathways are involved, is important because any intervention on 
the β-AR signaling pathway will cause a range of different responses. It is well established 
that β-AR signaling is down-regulated during heart failure (Lohse et al., 2003a; Nikolaev et 
al., 2010), however β-AR stimulation increases mortality in heart failure patients, while β-
blockers are extensively used in treatment of heart disease. Although β-blockers are used 
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successfully in heart failure to reduce cardiac work, it is clear that β-AR signaling is complex 
and upregulating specific effects of the β-AR may be beneficial to patients with cardiac 
disease. It has been demonstrated that there is compartmentalisation of β-AR signaling in 
the heart (Edwards et al., 2012), and therefore fully understanding these separate signaling 
pathways is crucial to developing more targeted and effective drugs for heart disease. 
It is also important to understand the regulation of CV in the heart: the “electrical 
wavelength” of the myocardium - determined by the ERP multiplied by the CV - is used to 
predict the likelihood of re-entrant arrhythmias. This concept was first discussed by 
Thomas Lewis in 1920 (Lewis, 1920), and Smeets et al. further developed its application to 
examining re-entrant arrhythmias. A lower wavelength creates a smaller re-entrant circuit 
which is more likely to be created and sustained by conduction block or areas of 
inhomogeneity (Smeets et al., 1986). More recently, it has been demonstrated that a low 
wavelength is a predictor of tachy-arrhythmias (Weiss et al., 2000). A decrease in CV would 
lower the wavelength and therefore increase the chance of re-entrant arrhythmias in the 
heart. These changes in CV can occur both at an ischemic region in the heart due to 
intracellular acidosis affecting gap junction conductance (Kléber et al., 1987) or through 
remodeling of gap junctions during heart failure (Severs et al., 2004; J. Smith et al., 1991). 
Therefore, understanding normal regulation and modulation of CV may be important in 
treating heart failure in the future. 
3.6.3 Limitations of Conduction Velocity Recordings 
CV was recorded using a fixed set of electrodes placed on the surface of the LV 
myocardium. This set of electrodes was freely able to rotate through 360⁰. As shown in fig. 
2.2.3, CV varies depending on the rotation of the electrode on the myocardium: this is due 
to its position relative to the fibre orientation. To keep CV as consistent as possible 
throughout experiments, CV was recorded as close to longitudinal fibre orientation as 
possible However, it is not possible to observe fibre orientation in the intact Langendorff 
preparation without high magnification optics. Therefore, it was necessary to estimate 
when the CV was at longitudinal CV - this was determined as the fastest CV observed as the 
electrode was rotated through 360⁰. This means there was an additional degree of 
variation in CVs recorded between different hearts. 
There seemed to be variation between different hearts in these experiments: basal CV 
recordings ranged from ~40cm/s to ~80cm/s. This could be due to a number of external 
factors, the most of likely of these being due to differences in position of the electrode 
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relative to fibre orientation and also due to slight differences in temperature of solution 
between experiments - reducing temperature decreases gap junctional conductance 
(Bukauskas and Weingart, 1993). For this reason, %Δ CV was calculated for all experiments. 
Any movement of the electrodes or preparation during the experiment would move the 
electrodes relative to fibre orientation and would cause a sharp peak or drop in CV. This 
would invalidate the experiment and for this reason some experiments had to be excluded 
from the results. This suggested the need for a mechanical uncoupler during these 
experiments to reduce the incidence of rapid discontinuities in the activation time 
recordings. 
3.6.4 Drug Interventions 
All drugs used in this study were perfused on via the method shown in fig. 2.6.1. Initially 
ISO was perfused on for 3mins (data not shown) however this was not long enough for the 
CV response to reach a near maximal response. 5min was then chosen for the incubation 
time. As seen in figs. 3.3.1 and 3.4.1, CV continued to increase following a 5min incubation 
period with both ISO and Fsk. Perfusion for more than 5mins was tried, however, the heart 
often became unstable during this time, sometimes developing arrhythmias. It was also a 
concern that incubation with ISO for a prolonged period would trigger the 
desensitization/β-arrestin response (Baillie et al., 2007; Lohse et al., 1992). Therefore, 5min 
was chosen as the optimal incubation time. Treatment with IBMX alone and with Fsk+IBMX 
appeared to reach near maximal response during the 5min perfusion with these drugs, 
therefore Fsk+IBMX was chosen as the intervention for future experiments raising cAMP. 
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4. Effect of β-adrenergic stimulation on the cardiac 
action potential and intracellular calcium transient 
4.1 Introduction 
Previous chapters have shown that β-adrenergic stimulation increases CV in ventricular 
muscle acutely. The main factors which affect ventricular CV are: cell size; gap junctional 
conductance (GJC) - due to either increased connexin or increased GJ permeability; and 
action potential shape. Specifically, the rate of rise (dV/dtmax) of the AP is a major 
determinant of CV: it is the source of the depolarising current which spreads between 
adjacent cells (Buchanan et al., 1985; Kléber and Rudy, 2004; Shaw and Rudy, 1997).  The 
AP upstroke is also indirectly influenced by β-AR stimulation through changes in diastolic 
interval, via influences on heart rate and APD (Ng et al., 2007; Taggart et al., 2003). 
Therefore, changes in both dV/dtmax and APD may have an influence on CV. 
There is no evidence to suggest the β-AR stimulation would alter cell size over short time 
periods (1-5mins). Therefore, to understand the mechanism by which β-AR stimulation 
increases CV, the most likely point at which to start would be either to look at the effect of 
β-AR stimulation on the cardiac AP or on GJC. 
This chapter looks at the effect of β-AR stimulation on the cardiac AP using both 
microelectrode recordings and the voltage-sensitive dye, Di-4-ANEPPS. Ca2+ transients were 
also recorded using the Ca2+ dye, Fura-4-AM. The incorporation of an LED light-guide into 
the electrodes used to record CV allowed the recording of AP and Ca2+ alongside CV at the 
same point on the myocardium. 
4.1.1 Effect of β-AR Stimulation on the Cardiac AP 
β-AR stimulation has multiple effects on cardiac AP shape. The upstroke of the AP - caused 
by the activation of voltage dependent Na channels (Nav1.5) is a major determinant of CV 
(Shaw and Rudy, 1997). Previous studies have shown that β-AR stimulation causes an 
increase in the magnitude of INa and AP dV/dtmax (Frohnwieser et al., 1997; Lu et al., 1999; 
Matsuda et al., 1992; Schreibmayer et al., 1994; Wang et al., 1996). However, in whole 
hearts sympathetic stimulation also increases the steepness of the slope of the APD 
restitution curve and reduces effective refractory period (ERP), which would in turn 
decrease the Na current (Ng et al., 2007; Taggart et al., 2003). Therefore, the effects of β-
AR on gNa is complex and its effects have not been extensively studied in the intact heart. β-
AR stimulation also influences APD and therefore diastolic interval: in large mammals, β-
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agonists increase IKs, causing shortening of the APD (Jost et al., 2005; Volders et al., 2003), 
preserving diastolic interval and maximizing time for Na channel recovery.  
Understanding the extent of the effect of β-AR stimulation on INa could indicate whether 
this change is responsible for the corresponding increase in CV. Recording AP amplitude, 
the rise time of the AP (TRise) and calculating the rate of rise (dV/dtmax) will all give an 
indication of the behavior of INa in response to β-AR stimulation. When considering AP 
amplitude as an indicator of INa, it is important to consider the effect of Ca2+ on the AP 
amplitude: studies carried out in the frog heart have indicated that an increase in 
extracellular Ca2+ leads to an increase in the AP amplitude (Niedergarke and Orkand, 1966). 
Therefore, dV/dtmax and TRise - which is also used to indicate the rate of rise of the AP – are 
considered better indicators of INa then AP amplitude.  Recording these changes at the 
same site and over the same time-course as the CV recordings is essential to understanding 
the effect of AP changes on CV. Our setup would not allow for microelectrode recordings at 
the site of the CV recordings, as the surface CV electrodes covered a large portion of the 
LV. Therefore, although the microelectrode is the more established method by which to 
measure cardiac APs - and allowed the calculation of dV/dtmax - the use of Di-4-ANEPPS and 
optical recordings of APs was a more valuable tool in understanding the impact of changes 
in AP on CV. 
4.1.2 Effect of β-AR Stimulation Ca2+ Handling in the Heart 
β-AR stimulation has a positive inotropic effect of the Ca2+ handling in cardiac myocytes. 
The L-type Ca2+ channel is a substrate for protein kinase A (PKA) - the main effector protein 
of β-AR signaling. On phosphorylation of the LTCC by PKA, ICa is increased (Bers, 2001; 
Reuter, 1987) increasing cytosolic Ca2+, SR Ca2+ content and thereby increasing the 
amplitude of the Ca2+ transient (Bers, 2002). The ryanodine receptor (RyR2) is also a target 
of PKA - this increases RyR2 sensitivity to Ca2+ (Bers, 2001) further facilitates calcium-
induced calcium release and therefore increases cytosolic [Ca2+] (Bers, 2002). This increase 
in systolic Ca2+ is largely responsible for the positive inotropic response to β-AR stimulation. 
The sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA2) is also a target for PKA 
phosphorylation following β-AR stimulation. Phospholamban (PLB) - an inhibitory protein 
which inhibits SERCA2 in the unphosphorylated state - relieves inhibition of SERCA2 when 
phosphorylated by PKA (Bers, 2001). This increases reuptake of Ca2+ from the cytoplasm 
and generates the positive lusitropy caused by β-AR stimulation. It also contributes to 
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positive inotropy - a combination of increased systolic Ca2+ and increased uptake by SERCA2 
increases the SR Ca2+ content (Bers, 2002). 
Recording Ca2+ alongside APs and CV allows a better understanding of the effect of β-AR on 
the cardiac AP and provides another possible mechanism for changes in CV. 
4.2 Methods 
4.2.1 Microelectrode Recordings 
Glass microelectrode recordings are the gold standard technique for measuring absolute 
transmembrane voltages. The sharp microelectrode technique was used to measure the 
electrical activity on a single cell as part of the intact myocardium, as previously carried out 
in this lab (Ghouri et al., 2015). This allowed recording of the AP at the same site and under 
similar conditions to the way CV recordings had previously been made.  
As described in 2.3, the heart was Langendorff perfused and orientated horizontally with 
the left ventricle facing upwards.  The heart was submerged in a specially designed Perspex 
waterbath containing Modified Tyrode's solution (93mM NaCl, 20mM NaHCO3, 1mM 
Na2HPO4, 1mM MgSO4.7H2O, 5mM KCl, 20mM Na+ acetate, 25mM glucose, 1.8mM 
Ca2+Cl) maintained at 37⁰C. The modified Tyrode’s solution also contained 3µM blebbistatin 
to prevent contraction of the heart and allow ME recordings. Sharp glass microelectrodes 
were pulled from borosilicate glass capillary pipettes of between 40-50MΩ tip resistance 
and were fillled with 1M KCl and a Ag/AgCl wire. Recordings were digitised at a sampling 
frequency of 28kHz. 
APs were recorded continuously where possible. However, as slight movement of the heart 
could disturb the microelectrode, this was often not possible. Therefore, recordings were 
made immediately prior to drug administration and at 1min, 3min and 5min during drug 
perfusion. Where possible an additional recording was made at 5min after drug 'wash-out.' 
The heart was LV paced continuously at 130ms intervals, as in the CV recordings, using 
bipolar platinum electrodes. Drug delivery occurred through the same syringe 
driver/syringe cannula system described in 2.6, however due to differences in the 
horizontal Langendorff system, drug was delivered via a syringe port immediately adjacent 
to the aortic cannula. As in the CV recordings, this ensured drug was delivered directly to 
the coronary vasculature. 
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4.2.2 Optrode Recordings 
The setup for the microelectrode recordings did not allow for the recording of CV during 
these experiments. To record AP and Ca2+ measurements alongside CV at the same site and 
time would allow better understanding of the interaction between these changes. 
Therefore, it was necessary to develop a method by which APs, Ca2+ transients and CV 
could be recorded simultaneously. 
The electrodes used to record CV were set into the centre of a fibre optic light guide. This 
allowed the transmission and collection of light from sites directly adjacent to the site at 
which CV was being recorded (2.4). Di-4-ANEPPS is well established as a voltage-sensitive 
dye, which has been used in single cell in multicellular preparations (Fluhler et al., 1985; 
Ghouri et al., 2015; Nygren et al., 2003). It is described in more detail in 2.4.1. 
Ca2+ sensitive dyes are also well established for use in recording intracellular Ca2+ 
transients. Fura dyes have been used in both single and 2-photon (2P) microscopy (Aistrup 
et al., 2009; Choi and Salama, 2000; Ghouri et al., 2015; Nishizawa et al., 2009). The dye 
used in these experiments was Fura-4-AM, a cell permeable version of Fura-4. This dye is 
discussed in more detail in 2.4.2. 
The 'optrode' setup allowed the recording of signals from the region of myocardium 
directly adjacent to the site at which CV was recorded. These were not single cell 
recordings, but a sum of the electrical activity and Ca2+ signals from epicardial cells over a 
small - ~1cm3 - region. 
Background recordings were made prior to the addition of Fura-4-AM or Di-4-ANEPPS. 
30μM Fura-4-AM in Tyrode's solution was perfused into the heart over 5min. The perfusion 
was then switched back to Tyrode's and the preparation was left for a further 10min to 
allow the acetoxymethyl groups to be removed by intracellular esterases and for the heart 
to reach a steady state. At the end of this time, 50μl Di-4-ANEPPS (2mM) was added as a 
bolus. 
4.2.3 Drug Intervention 
30μM Fsk was used in the microelectrode experiments, as in 3.4 treatment with Fsk 
appeared to create the largest response of the interventions used (Fig. 3.4.1). However, it 
was later decided that 1μM Fsk and 100μM IBMX used together was a better intervention 
which was more stable and had a lower risk of causing non-specific effects. Therefore, 
Fsk+IBMX was used in the optrode experiments. 
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In both the microelectrode and optrode experiments, drug was perfused on continuously 
for 5min using the method described in 2.6. 
Results 
4.3 Microelectrode Recordings 
30μM Fsk was perfused into the heart for 5 min. Fig. 4.3.1A shows the time-course of these 
experiments alongside sections of example trace from each of the main time-points below. 
The resting membrane potential was recorded as -80mV and did not appear to change 
throughout the experiment. Fsk did not significantly change TRise (rise time of the upstroke 
between 10-90. AP amplitude also did not change significantly (12.6±3.8%, mean±SEM, 
n=4; 4.3.1 B). The TRise is a good indicator of dV/dtmax and is used to represent this in the 
optrode experiments. However, with microelectrode recordings it was also possible to 
calculate dV/dtmax. Actual values of dV/dtmax are shown in Fig. 4.3.1 D, to demonstrate that 
these were within expected values and that there was little variation between 
experiments. There was also no significant change in dV/dtmax. 
The greatest impact of Fsk was seen on the APD. APD is shown at 50%, 75% and 90% of the 
repolarisation. Fsk caused a rapid and significant increase in APD50, 75 and 90, increasing 
to near maximal response within the first minute of drug perfusion (Fig. 4.3.1 E). APD50 
increased by 90±20% (mean±SEM, n=4) at the maximal point of the response. APD75 
increased by 60±10% (mean±SEM, n=4) and APD90 increased by 30±10% (mean±SEM, n=4). 
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Figure 4.3.1 Raising cAMP prolongs APD in the intact rat heart  
 A) Example APs from a single experiment. The top line shows sections of the original trace from the 
experiment at each of the recording points. Data is represented in bar graph as the mean response ± 
SEM. Below shows a single AP which is an average of 5s recording. White bars indicate the control 
recording taken prior to adding Fsk, grey indicates time-points at which recordings were taken during 
Fsk perfusion and black indicates the washout period. B) There was no significant increase in APA in 
response to Fsk (n=4). C) There was no significant change in AP rise time in response to Fsk (n=4). D) 
Maximum rate of rise of the AP (Vmax) was calculated by differentiating the AP with respect to time. 
Treatment with Fsk did not significantly change Vmax (n=4). E) Fsk significantly prolonged the rat AP 
at 50, 75 and 90% (n = 4 for everything except wash out, which n=2). (*=p<0.05; **=p<0.01). 
Annabel Campbell 2017 
 
    76 
 
4.4 Optrode Recordings of the action potential show that β-AR 
stimulation prolongs APD and increases AP amplitude in the intact 
rat heart 
A combination of 1μM Fsk and 100μM IBMX were perfused into the heart to raise cAMP.  
Fsk+IBMX significantly increased APA (AP amplitude) to a maximum of 8.2±3.2% and by 
20.2±4.4% when compared to the DMSO control (p<0.001, control n=3, Fsk+IBMX n=6; Fig. 
4.4.1 B). There was no significant difference in TRise between Fsk+IBMX and the DMSO 
control at any point during drug perfusion (Fig. 4.4.1 C). 
Fsk+IBMX significantly increased APD at APD50, 75 and 90 (Fig 4.4.1 E-F). APD50 was 
increased by a maximum of 60.1±11.7% (p<0.001, control n=3, Fsk+IBMX n=6); APD75 was 
increased by a max of 53.2±4.6% (p<0.001 control n=3, Fsk+IBMX n=6); APD90 was 
increased by 32.6±4.7% (p<0.001 control n=3, Fsk+IBMX n=6). The change in APD was rapid 
with maximal values reached within 2min of drug perfusion. 
The effect of 100nM isoproterenol on AP was also recorded. ISO significantly increased APA 
by 10.6±5.0% compared to a time control (P<0.05, n=4; Fig 4.4.2 A). As with Fsk + IBMX, 
there was no significant change in TRise in response to ISO (Fig. 4.4.2 B). ISO prolonged 
APD50 and 90, but to a lesser extent than Fsk+IBMX (Fig 4.4.2 C-E). APD50 was prolonged 
by a maximum of 18.1±7.9% (p<0.05, n=4). APD75 was slightly prolonged by perfusion with 
ISO but this change was not significant. Finally, APD90 was significantly prolonged by ISO to 
a maximum of 8.7±6.2% (p<0.05, n=4). 
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Figure 4.4.1 Raising cAMP increases action potential amplitude (APA) and prolongs action 
potential duration (APD) in the intact rat heart 
A) Example APs from a single experiment.  The top line shows sections of the original trace from 
immediately prior to drug addition and at 1, 3 and 5min during drug perfusion. Below shows a single 
AP for each time point which is an average of 5s recording. Data are shown as the mean at individual 
time points B) Treatment with Fsk+IBMX significantly increased APA. 90s-300s p<0.001 (Control n=3, 
Fsk+IBMX n=6) C) There was no significant change in AP rise time in response to Fsk+IBMX (Control 
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n=3, Fsk+IBMX n=6). D) Fsk+IBMX significantly prolonged the rat AP at 50% (APD50). At 90s p<0.01. 
120s-300s p< 0.001 (Control n=3, Fsk+IBMX n=6). E)  Fsk+IBMX significantly prolonged the rat AP at 
75% (APD75). 90s-300s p< 0.001 (Control n=3, Fsk+IBMX n=6). F) Fsk+IBMX significantly prolonged 
the rat AP at 90% (APD90). At 90s-300s p< 0.001 (Control n=3, Fsk+IBMX n=6). 
 
Figure 4.4.2 β-adrenergic stimulation with isoproterenol (ISO) increases action potential amplitude 
(APA) and prolongs action potential duration (APD) in the intact rat heart 
Data shown as mean at individual time points. A) Treatment with ISO significantly increased APA. 
120s-240s p<0.05 (n=4) B) There was no significant change in AP rise time in response to ISO (n=4). C) 
ISO did not significantly prolong rat AP at 50% (APD50 (n=4)). D) ISO prolonged the rat AP at 75% 
(APD75) but the change was not significant (n=4). E) ISO significantly prolonged the rat AP at 90% 
(APD90). At 180s-300s p< 0.05 (n=4). 
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4.5 β-AR increases calcium transient amplitude and shortens the 
later phases of the calcium transient 
Using the Ca2+ sensitive dye, Fura-4, Ca2+ transients were recorded alongside the AP 
recordings. Fig. 4.5.1 A shows an example section of AP trace and the corresponding 
averaged AP, and below that is the averaged Ca2+ transient from the same time-point. 
1μM Fsk + 100μM IBMX were again used to raise intracellular cAMP. Fsk+IBMX did not 
significantly affect the Ca2+ transient baseline and therefore diastolic Ca2+ (n=4; Fig.4.5.1 B). 
Fsk + IBMX significantly increased the Ca2+ transient amplitude, increasing it by 100.3±7.4% 
(n=4, Fig. 4.5.1C). 
Fsk+IBMX also decreased the rise time of Ca2+, suggesting an increase in rate of rise of the 
Ca2+ transient (Fig 4.5.1 D). TRise 10-90% was reduced by 11.9±3.0% at its lowest point 
(p<0.05, n=4). Raising cAMP did not significantly alter Ca2+ duration (CaD) at 50% (Fig.4.5.1 
E), however it shortened Ca2+ transient duration at CaD75 and CaD90 (Fig 4.5.1 F-G). 
Fsk+IBMX shortened CaD75 by 11.1±1.4% (p<0.05, n=4) and CaD90 by 15.0±1.3% (p<0.001, 
n=4). 
100nM ISO was used to measure the effect of β-AR stimulation on the Ca2+ transient (Fig. 
4.5.2). ISO had no significant effect on diastolic Ca2+ (Fig. 4.5.2 A). As with raising 
intracellular cAMP, ISO significantly increased Ca2+ transient amplitude by 73.8±10.0% at its 
highest point (p<0.001, n=4; Fig. 4.5.2B). ISO also reduced TRise 10-90% to a maximum 
response of 9.0±1.8% (p<0.001, n=4; Fig.4.5.2 C), indicating an increase in the rate of rise of 
the Ca2+ upstroke. As with Fsk+IBMX, ISO had no effect of CaD50, but shortened the Ca2+ 
transient duration at 75 and 90% (Fig. 4.5.2 D-E). CaD75 was shortened by 11.6±1.3% 
(p<0.05, n=4) and CaD90 was shortened by  18.6±1.2% (p<0.001, n=4). 
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Figure 4.5.1 Raising cAMP increases calcium transient amplitude (CaA) and shortens the later 
stages of the calcium transient in the intact rat heart 
A) Example APs and Ca2+ transients from a single experiment. The top line shows sections of the 
ratioed AP trace from immediately prior to drug addition and at 1, 3 and 5min during drug perfusion. 
Below shows a single AP for each time point which is an average of 5s recording. The bottom row 
shows a single averaged Ca2+ from 5s of recording at the same time points as the APs. B) Fsk+IBMX 
had no significant effect on the baseline of the Ca2+ transient (n=4). C) Treatment with Fsk+IBMX 
significantly increased CaA. 120s-300s p<0.001 (n=4) D) Fsk+IBMX significantly shortened Ca2+ rise 
time. 90s-300s p<0.05 (n=4). E) Fsk+IBMX did not significantly affect Ca2+ transient duration (CaD) at 
50% (CaD50) (n=4). F) Fsk+IBMX significantly shortened the Ca2+ transient duration at 75% (CaD75). 
120s-300s p< 0.05 (n=4). G) Fsk+IBMX significantly shortened the Ca2+ transient duration at 90% 
(CaD90). At 60s, p<0.05 and at 120s-300s p< 0.001 (n=4). 
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Figure 4.5.2 β-adrenergic stimulation with isoproterenol (ISO) increases calcium transient 
amplitude (CaA) and shortens the later stages of the calcium transient in the intact rat heart 
A) ISO had no significant effect on the baseline of the Ca2+ transient. (n=4) B) Treatment with ISO 
significantly increased CaA. 120s-300s p<0.001 (n=4) C) ISO significantly shortened Ca2+ rise time. At 
240s p<0.05 and at 300s p<0.001 (n=4). D) ISO did not significantly affect CaD at 50% (CaD50 (n=4)). 
E) ISO significantly shortened the Ca2+ transient duration at 75% (CaD75). 120s-300s p< 0.05 (n=4). F) 
ISO significantly shortened the Ca2+ transient duration at 90% (CaD90). At 120s-300s p< 0.001 (n=4). 
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4.6 Discussion 
4.6.1 β-AR Stimulation Increases AP Amplitude but Does Not Affect dV/dtmax 
Phase 0 of the cardiac AP is the upstroke of the AP: in the ventricle, this upstroke is 
determined largely by the Na+ current (INa) which is caused by the activation of voltage 
sensitive Na channels (Nav1.5) (Levick, 2000). As previously discussed, the upstroke is a 
major determinant of CV: it is the source of the depolarising current which spreads 
between adjacent cells (Buchanan et al., 1985; Kléber and Rudy, 2004; Shaw and Rudy, 
1997).  It has been previously demonstrated the β-AR stimulation increases the magnitude 
of INa and increases the rate of rise of the AP, or dV/dtmax (Frohnwieser et al., 1997; Lu et al., 
1999; Matsuda et al., 1992; Schreibmayer et al., 1994). However, INa is also indirectly 
influenced by β-AR stimulation through changes in diastolic interval, via influences on heart 
rate and APD (Ng et al., 2007; Taggart et al., 2003), therefore the effect of β-AR on INa and 
dV/dtmax, in the intact myocardium is complex. 
Although it is possible to measure INa in the intact heart, these experiments are technically 
extremely challenging. Therefore, both AP amplitude and dV/dtmax were shown to 
represent changes in gNa. The relationship between gNa and dV/dtmax is approximately linear, 
and theoretical and experimental studies have suggested that a 40% increase in gNa would 
increase dV/dtmax by approximately 20% (Berecki et al., 2010, Buchanan et al., 1985; Cohen 
et al., 1984, 1981).  
The microelectrode study showed an insignificant increase in APA and no change in the AP 
TRise (Fig. 4.3.1B and C). dV/dtmax was calculated and Fsk did not significantly affect 
dV/dtmax. This suggests that raising cAMP via Fsk did not affect gNa and therefore was not 
the mechanism behind the previously recorded change in CV. However, it is important to 
note that APA is one of the more difficult parameters to record via sharp microelectode, as 
the slightest movement of the microelectrode would influence APA. Therefore, the trend 
towards an increase in APA may have become significant with further experiments. 
This is supported by the significant increase in APA in response to both Fsk and ISO 
recorded in the optrode experiments. An increase in APA could suggest an increase INa, 
however this increase was not large enough to significantly affect dV/dtmax or TRise. The 
largest increase in APA recorded in these experiments was 10.6%, which would correspond 
to only a 5% increase in dV/dtmax. Again, it is important to consider the possible influence of 
Ca2+ on the AP amplitude – experiments in 4.5 show an increase in CaA in response to 
Fsk+IBMX. Therefore, the calculated dV/dtmax values are a better indicator of gNa than APA.  
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Change in amplitude in response to Fsk may have been underestimated due to bleaching or 
wash-out of Di-4-ANEPPS - this is further discussed in 4.6.4. 
The relationship between dV/dtmax and CV is also not clear. Darrow et al. reported increases 
in CV in cultured rat neonatal cardiac cells without any reported increase in dV/dtmax 
(Darrow et al., 1996), whereas De Boer et al. carried out a similar study in neonatal rat cells 
and found a corresponding increase in dV/dtmax (de Boer et al., 2007). Studies carried out in 
the intact ventricle have shown that dV/dtmax is proportional to CV2 (Buchanan et al., 1985; 
Cohen et al., 1984). Therefore, if the recorded change in amplitude did correspond to 
approx. 5% increase in dV/dtmax, it would only produce an approx. 2% increase in CV. So, 
although these experiments indicate a possible increase in gNa, this increase is not large 
enough to account for the full extent of the CV recorded. Using the square-law relationship, 
an increase in CV of 10% would require an increase dV/dtmax of 25%, a result not reported 
or observed in this study. It is also important to consider that the linear relationship 
between dV/dtmax and CV2 exists in a uniform, linear cable (Buchanan et al, 1985), whereas 
in the intact myocardium the relationship will be more complex. 
4.6.2 β-AR Stimulation Prolongs APD in the Rat Heart 
It is well established that in larger mammals, β-AR causing shortening of the cardiac AP 
(Jost et al., 2005; Volders et al., 2003). However, in these experiments both Fsk+IBMX and 
ISO caused the opposite response: significant prolongation of action potential duration. 
The slow outward K+ current (IKs) is a substrate for PKA and β-AR stimulation causes an 
increase in IKs (Walsh et al., 1988; Walsh and Kass, 1988), causing the shortening of the APD 
in larger mammals. However, in rats and mice, the amplitude of both IKs and IKr are both 
much lower than in larger mammals, with a smaller relative contribution to repolarisation 
(Varró et al., 1993). Therefore, an increase in IKs in response to β-AR stimulation would not 
be sufficient to shorten the rat APD. This means that the influence of Ca2+and its reuptake 
by the SR has a greater influence on the repolarisation of the rat AP. As shown in Fig. 4.5.1 
and 4.5.2, β-AR stimulation significantly increases the amplitude of the Ca2+ transient 
through a combination of increased ICa, increased SR Ca2+ uptake as discussed in 4.1.2. 
Although the Ca2+ transient is shortened at 75 and 90% by treatment with β-AR stimulation 
(Fig. 4.5.2 E&F), the large increase in CaA causes an increase in mean Ca2+.  The overall 
effect of these changes on the AP in larger mammals is to elevate the plateau phase of the 
AP (Bers, 2001). The rat AP is shorter and lacks the plateau phase, therefore the increase in 
systolic Ca2+ instead affects AP repolarisation and prolongs APD. 
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This changes the effect of β-AR on effective refractory period (or ERP) in rats compared 
with larger mammals, which - as previously discussed - is an important determinant of 
calculating 'wavelength' and therefore predicting the likelihood of arrhythmias. This 
highlights a need to carry out further work studying the effect of β-AR stimulation on CV in 
larger mammal hearts, for example rabbits, which have a more similar cardiac AP to 
humans than rats. However, the changes shown in these experiments are rate independent 
changes in the AP and ERP due to pacing continuously throughout the experiment. The 
increase in HR caused by β-AR stimulation shortens ERP, and this effect occurs across 
species (Erlij and Mendez, 1964; Ng et al., 2007). 
4.6.3 β-AR Stimulation Increases Ca2+ Transient Amplitude and Shortens 
Transient Duration 
The largest response to β-AR recorded in these experiments was the increase in Ca2+ 
transient amplitude (Fig 4.5.1, Fig. 4.5.2); Fsk+IBMX increased Ca2+ by as much as 
100.3±7.4%. This is in line with previous studies, which suggest this increase is due to a 
combination of factors, including phophorylation of the LTCC and increase of ICa (Bers, 
2001; Kamp and Hell, 2000), increased SR content via stimulation of SERCA due to PLB 
phosphorylation (Bers, 2001), and increased Ca2+ release from RyR2 (Bers, 2002). β-AR 
stimulation also shortened the Ca2+ at CaD75 and CaD90. This was also in line with 
previously studies, which suggest this is due phosphorylation of PLB by PKA which reduces 
the inhibitory effects of PLB on SERCA2, and due to faster Ca2+ mediated inactivation of the 
LTCC (Bers, 2002). 
It is clear there is a large change in systolic Ca2+ during drug perfusion over the same time 
period as the changes in CV. Changes in Ca2+ have a number of effects in the cell: apart 
from the obvious positive inotropic and lusitropic effects previously discussed, Ca2+ is also 
involved in intracellular signaling through the calcium/calmodulin-dependent protein 
kinase (CaMKII) (Grimm and Brown, 2010).  
Therefore, although Ca2+ is not typically considered as a factor which could increase CV it is 
important to consider the multiple potential roles of Ca2+ in intracellular signaling. Raised 
intracellular Ca2+ has previously been shown to decrease gap junctional conductance, 
though it has been described as a small response which is more dependent on changes in 
intracellular pH (De Mello, 1975; Loewenstein, 1981; Spray et al., 1985). Therefore, further 
study on the effect of raised Ca2+ on CV in the intact heart is required. 
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4.6.4 Limitations of Optical Recordings 
Although optical recordings of APs and Ca2+ transients provided many advantages during 
this study, there were limitations to these techniques, particularly when studying both Ca2+ 
and voltage at the same time. Although a background recording was taken before each 
experiment, this background recording was made before the addition of either Di-4 or 
Fura-4-AM. For accurate measurements of [Ca2+], background subtraction from the Ca2+ 
signal is required. Due to the fact perfusion of Fura-4-AM and cleaving of the ester groups 
took in total 20min, Di-4 ANEPPS needed to be added after Fura-4-AM to prevent it from 
being washed out before the experiment. Therefore, the background recordings had to be 
taken in the absence of Di-4-ANEPPS, which was less accurate than taking a background in 
the presence of Di-4-ANEPPS. This did not affect the recordings of the time-course of the 
Ca2+ transient or the relative changes in amplitude recorded, therefore its impact on these 
experiments was small. 
Both Vm and Ca2+ results are taken from an area on the surface of the heart, rather than a 
single cell. Although this meant that a larger number of cells were being sampled, this 
meant that there was a degree of difference in the time until activation (TAct) between cells. 
This could cause a 'smearing' of the action potential upstroke when averaging signals from 
a region of cells - the action potential upstroke would appear slower due to the range of 
APs being averaged. Due to the speed of the AP upstroke, this was the only measurement 
affected by this: APD, Ca2+ upstroke and Ca2+ transient duration would not be significantly 
affected by this due to their longer time-course. Reporting results as relative change 
reduced the impact of this, and our results were confirmed with the microelectrode 
recordings. 
Recording from a region of cells would also make it impossible to quantify [Ca2+]. Instead 
relative change in fluorescence was recorded, and changes in the Ca2+ reported as relative 
change. 
Finally, there was also an issue with Di-4-ANEPPS bleaching and washing out during 
experiments. A decrease in APA was recorded over control conditions (Fig. 4.4.1 B). 
Although an increase in APA was recorded in response to Fsk+IBMX, it is possible a greater 
response was partially masked by this decrease in the control. The most likely cause for this 
decrease in APA is the bleaching of Di-4-ANEPPS or the washout of the dye during the 
experiment. 
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5. The Effect of Calcium on Ventricular Conduction 
Velocity  
5.1 Introduction 
Previous experiments have demonstrated an increase in CV of ~8% in response to 
treatment with the β-agonist ISO and of ~10% in response to treatment with the cAMP 
raising drugs Fsk and IBMX (Chapter 3). Experiments with both microelectrode and voltage-
sensitive dyes suggested that changes in the AP were not sufficient to fully explain the 
mechanism behind these changes in CV in response to β-AR stimulation. These experiments 
also recorded the effects of β-AR stimulation on the Ca2+ transient. A large increase in the 
Ca2+ amplitude of ~100% was recorded in response to raising cAMP (Chapter 4) and this 
change occurred over the same time-course as the CV response to β-AR stimulation. A 
change in Ca2+ transient amplitude signifies at large increase in intracellular systolic [Ca2+]. 
This change in Ca2+ may have had some impact on CV, and therefore the next step of this 
study was to examine the effect of Ca2+ alone on CV in the heart. 
Increased intracellular [Ca2+] is typically thought to have a negative impact on CV - previous 
studies have shown that increased intracellular Ca2+ decreases gap junctional conductance 
(GJC) (De Mello, 1975; Loewenstein, 1981; Spray et al., 1985), which would also decrease 
CV. However, Ca2+ also plays a role in intracellular signaling through activation of Ca2+ 
sensitive kinases and phosphatases, particularly the Ca2+/calmodulin-dependent protein 
kinase (CaMKII), which has many diverse roles throughout the cell (Grimm and Brown, 
2010) - this is further discussed in 6.1.3. 
Initial experiments raised and lowered extracellular Ca2+ to measure the effect [Ca2+] on CV. 
However, it was not clear if this change in extracellular concentration was enough to alter 
intracellular CV as no significant change in Ca2+ amplitude was recorded (5.3.2 D). 
Therefore, following experiments looked at the effect of the LTCC inhibitor Nifedipine on 
CV: the LTCC is a substrate for PKA and is phosphorylated in β-AR stimulation. This 
increases ICa and is the primary way β-AR increases the amplitude of the Ca2+. Therefore, 
inhibition of LTCC would be expected to attentuate the CV response if it were mediated by 
Ca2+. 
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5.2 Methods 
CV measurements were recorded as described in 2.2. AP and Ca2+ recordings were made 
alongside CV using the 'optrode' setup described in 2.4. APs were recorded using the 
voltage sensitive dye: Di-4-ANEPPS. Ca2+ transients were recorded using the Ca2+ sensitive 
dye: Fura-4-AM. 
5.2.1 Altering Extracellular Ca2+ 
To raise extracellular Ca2+ for a 5min period, the heart was perfused with Tyrode's solution 
with (normal) 1.8mM Ca2+ as described in 2.1. A glass syringe was loaded with a high Ca2+ 
Tyrode's solution which, on mixing with the perfusate, would result in a final [Ca2+] of 
3.6mM. The high Ca2+ solution was delivered to the heart as described in 2.6. To reduce 
extracellular Ca2+, Tyrode's with a [Ca2+] of 1mM was perfused onto the heart. A glass 
syringe was loaded with high Ca2+ so that when the syringe driver was turned on, the final 
[Ca2+] reaching the heart was 1.8mM. The syringe driver was switched on from the 
beginning of the experiment and switched off to lower Ca2+ perfusing the heart to 1mM 
during discrete period (5mins) before switching the perfusion syringe on again to restore 
1.8mM Ca2+. 
5.2.2 Drug Delivery 
1μM Nifedipine (Sigma Aldrich, UK) was used to inhibit the LTCC. In 5.3.3, Nifedipine was 
perfused into the heart using the syringe driver setup described in 2.6. In 5.4.1, 1μM 
Nifedipine was perfused onto the heart with Tyrode's solution for 10min prior to the 
experiment. Fsk+IBMX were perfused into the coronary vasculature using the syringe driver 
setup shown in 2.6  
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Results 
5.3 Raising extracellular Ca2+ decreases Ventricular Conduction 
Velocity 
To study the effect of raising or lowering Ca2+ on CV, extracellular Ca2+ was either increased 
to 3.6mM or reduced to 1mM for a 5min period. CV, AP and Ca2+ transients were recorded 
over this time. Fig.5.3.1 A shows example averaged Ca2+ transients from individual 
experiments: it shows the Ca2+ in normal [Ca2+], followed by the Ca2+ transient after Ca2+ has 
been reduced to 1mM or increased to 3.6mM. Increasing extracellular [Ca2+] to 3.6mM 
significantly decreased CV by 7.3±3.0% when compared with a time control (p<0.05, n=4; 
Fig. 5.3.1). Decreasing extracellular [Ca]2+ to 1mM increased CV by 6.9±6.3%. This increases 
was not significant when compared to a time control (control n=4, Low Ca2+ n=3). 
Changing extracellular [Ca2+] did not significantly affect Ca2+ transient baseline - or diastolic 
Ca2+ - until 300s where high Ca2+ increased diastolic Ca2+ by 5.0±1.8% (p<0.05, Control and 
high Ca2+ n=4, low Ca2+ n=3; Fig 5.3.1 D). However, there was an upward drift in the control, 
and in both low and high [Ca2+] traces. These experiments are shown without background 
subtraction in Fig. 5.3.1; Fig. 5.3.2 compares these data with the background subtracted 
data for diastolic Ca2+.  An increase in diastolic Ca2+ is seen in the example traces for high 
[Ca2+]: this increase was seen in some but not all experiments, and is line with reported 
changes in the literature (Bers, 2002). The variability in diastolic Ca2+ recordings may be due 
to the sensitivity of Fura-4, and is further discussed in 5.5.2. 
Increasing extracellular [Ca2+] to 3.6mM significantly increased Ca2+ transient amplitude by 
32.2±5.2% at its maximal point (p<0.001, n=4; Fig. 5.3.1 E). Decreasing extracellular [Ca2+] 
to 1mM decreased Ca2+ transient amplitude but this change was not significant until 300s 
(p<0.05 control  n=4, low Ca2+n=3; Fig. 5.3.1 E). Altering extracellular Ca2+ did not 
significantly affect Ca2+ duration at 90% (control, high Ca2+ n=4, low Ca2+ n=3; Fig 5.3.1 F). 
The change in extracellular Ca2+ did not significantly affect the cardiac AP, with no change 
in APA, TRise or APD90 between high or low Ca2+ when compared with the time control 
(Fig. 5.3.1 G, H and I). However, there was a downward drift in APA over time, which may 
be due to Di-4 bleaching or wash-out, as discussed in 4.6.4. 
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Figure 5.3.1 Raising extracellular Ca2+ decreases CV, while lowering extracellular Ca2+ increases CV 
in the intact rat heart. 
 A) Example averaged Ca2+ transients from a single low Ca2+ (1mM) and a single high Ca2+ (3.6mM 
Ca2+) experiment. Transients from pre-and post changing extracellular Ca2+ concentration are shown. 
B) Example CV traces from single experiments showing the effect of high extracellular Ca2+ and low 
extracellular Ca2+ on CV. C) Decreasing extracellular Ca2+ causes an increase in CV which is not 
significant when compared to a time control (low Ca2+ n=3, time control n=4). Increasing extracellular 
Ca2+signficiantly decreases ventricular CV (120-270s p<0.05 or less, n=4) when compared to a time 
control. Low Ca2+ is significantly different from high Ca2+ (at 90s p<0.01, 120-300s p<0.001. High Ca2+ 
n=4, low Ca2+n=3). D) The change in extracellular Ca2+ did not significantly affect the Ca2+ transient 
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baseline (Control n=4, High Ca2+ n=4, low Ca2+n=3) until 300s where 1mM Ca2+ was significantly 
higher vs. time control (P<0.05 Control n=4, low Ca2+n=3). E) Increasing extracellular Ca2+ to 3.6mM 
significantly increased Ca2+ transient amplitude (60-180s p<0.001, n=4; 300s p<0.001 n=4). 
Decreasing extracellular Ca2+ to 1mM decreased Ca2+ amplitude but this change was not significant 
until 300s (p<0.05 time control  n=4, low Ca2+n=3). F) The change in extracellular Ca2+ did not 
significantly affect the duration of the Ca2+ at 90% (CaD90) (Control n=4, High Ca2+ n=4, low Ca2+n=3). 
G, H, I) The change in extracellular Ca2+ did not significantly affect the cardiac action potential 
(Control n=4, High Ca2+ n=4, low Ca2+n=3). 
The Fura-4 ratio signals that represent intracellular Ca2+ concentration results shown in Fig 
5.3.1 were measured without subtraction of background fluorescence: this means that the 
ratio signal is not purely due to Fura-4 fluoresence but also has contributions from 
backgroud light/intrinsic fluorescence. Thus, loss of Fura4 signal due to loss of dye or 
bleaching cannot be properly compensated by ratiometry since the significant fixed 
contribution of background fluorescence to both ordinate and abscissa would result in 
inappropriate ratio values. This may account for the apparent increase in fluoresence ratio 
baseline show in Fig. 5.3.1 C and again in Fig. 5.3.2A. Fig. 5.3.2 C and D show the same Ca2+ 
transient baseline and amplitude graphs as A and B, but a background recording - where 
fluorescence from the preparation has been recorded before the addition of Fura-4-AM - 
has been subtracted from the traces prior to analysis. 
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Fig. 5.3.2 Background subtraction gives a more accurate indication of Ca2+ transient baseline and 
amplitude. 
A, B) show the Ca2+ transient baseline and amplitude analysed from Ca2+ ratioed without background 
subtraction, as shown in fig. 5.3.1. C, D: show Ca2+ transient baseline and amplitude analysed from 
Ca2+ ratioed after background subtraction. C) The change in extracellular Ca2+ did not significantly 
affect the Ca2+ transient baseline (Control n=4, High Ca2+ n=4, low Ca2+n=3). D) The change in 
extracellular Ca2+ did not significantly affect the Ca2+ transient amplitude (Control n=4, High Ca2+ n=4, 
low Ca2+n=3). 
In the background subtracted experiments, there is no significant change in the Ca2+ 
transient baseline in response to raising extracellular [Ca2+] to 3.6mM or reducing it to 
1mM (control and high Ca2+ n=4, low Ca2+n=3; Fig. 5.3.2 C). However, there is also no 
significant change in Ca2+ transient amplitude in response to high or low Ca2+ (control and 
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high Ca2+ n=4, low Ca2+n=3). There is still a trend towards an increase in Ca2+ transient 
amplitude in response to high Ca2+ and a trend towards a decrease in Ca2+ amplitude in 
response to low Ca2+, however these changes are small and not significant. 
Therefore, it is not clear whether the changes in extracellular Ca2+ are also causing changes 
in intracellular Ca2+. This may due to small changes being difficult to detect on this system 
or due to the sensitivity of Fura-4-AM - this is discussed further in 5.5.5. Regardless, the 
changes in amplitude recorded are much lower than the corresponding increase in systolic 
Ca2+ recorded in response to β-AR. 
To study the effect of changing systolic Ca2+ on CV, the LTCC inhibitor Nifedipine was used, 
which would decrease systolic Ca2+ and therefore decrease Ca2+ transient amplitude. These 
experiments have a n=2, therefore individual traces fro these experiments are shown. 1μM 
Nifedipine was perfused into the heart for 5min. Nifedipine cause a small increase in CV of 
5.6% at its maximal in one trace, but no increase in the second (Fig. 5.3.2 B). Nifedipine did 
not affect diastolic Ca2+ (Fig 5.3.2 C) or Ca2+ transient duration at 90% (Fig.5.3.2 E). 
However, Nifedipine did decrease Ca2+ transient amplitude by 45% at its maximal response 
(Fig 5.3.2 D). 
There was no change in the amplitude or the TRise of the AP in response to Nifedipine (Fig 
5.3.2 F and G). However, incubation with Nifedipine decreased APD90 by 27%. 
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Fig. 5.3.3 Inhibition of L-type Ca2+ channel with 1μM Nifedipine increases CV but not to extent of 
cAMP response.  
A) Example trace showing the raw CV response to Nifedipine. B) % change in CV in response to 
treatment with Nifedipine. Traces show mean control (black), and the individual Nifedipine traces 
Nifedipine 1 (grey) and Nifedipine 2 (red).  Nifedipine appears to increase CV in one experiment but 
not in the second. Stats could not be calculated due to the n=2. C) Nifedipine does not affect the Ca2+ 
transient baseline. D) Nifedipine decreases Ca2+ transient amplitude. E) Nifedipine does not affect 
Ca2+ transient duration at 90%. F) Nifedipine does not significantly affect AP amplitude. G) Nifedipine 
does not significantly affect the TRise of the AP. H) Nifedipine significantly decreases APD at 90%. 
  
Annabel Campbell 2017 
 
    94 
 
5.4 Inhibiting the L-type Calcium Channel with Nifedipine does not 
Affect the Conduction Velocity Response to Forskolin and IBMX 
Although increasing intracellular Ca2+ appears to decrease CV (Fig. 5.3.1 B), the opposite of 
the CV change which accompanies the increase of systolic Ca2+ in β-AR stimulation, β-AR 
signaling and its interaction with Ca2+ is complex. Therefore, to understand whether the 
increase in CV in response to β-AR stimulation is Ca2+ independent, the response to 
Fsk+IBMX was recorded in the presence of 1μM Nifedipine. 
 
Fig. 5.3.4 CV increases significantly in response to Fsk+IBMX in the presence of the L-type Ca2+ 
inhibitor Nifedipine (1μM). 
A) Example CV traces from individual experiments showing a DMSO control (black), the CV response 
to Fsk+IBMX-Nifedipine (grey), and Fsk+IBMX+Nifedipine. B) % change in CV in response to fsk+IBMX 
± Nifedipine. The CV response is not significantly different between Fsk + IBMX ± Nifedipine (n=4). 
Fsk+IBMX in the presence of Nifedipine significantly increased CV compared to the DMSO control 
(150-300s p<0.001, n=4). C, D) The APA and TRise response to Fsk+IBMX are also not significantly 
different ± Nifedipine (control n=3, Fsk+IBMX-Nifedipine n=6, Fsk+IBMX+Nifedipine n=4). E) 
Fsk+IBMX+Nifedipine significantly prolongs APD at 90% when compared to the control (240-300s 
p<0.05; control n=3, Fsk+IBMX-Nifedipine n=6, Fsk+IBMX+Nifedipine n=4). APD90 prolongation is not 
significantly different between Fsk+IBMX±Nifedipine (control n=3, Fsk+IBMX-Nifedipine n=6, 
Fsk+IBMX+Nifedipine n=4). 
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Fsk+IBMX increased CV by 12.5±1.5% in the presence of Nifedipine (p<0.001, n=4; Fig 5.4.1 
B). The increase in CV was not significantly different between Fsk+IBMX±Nifedipine (n=4). 
The APA and TRise response to Fsk+IBMX was not significantly different ±Nifedipine 
(Control, Fsk +IBMX+Nifediepine n=4, Fsk+IBMX-Nifedipine n=6; Fig 5.4.1 C and D). APD90 
was significantly prolonged by Fsk+IBMX both in the presence and absence of Nifedipine 
(p<0.001 Control, Fsk +IBMX+Nifediepine n=4, Fsk+IBMX-Nifedipine n=6; Fig. 5.4.1 E). 
Although prolongation of the AP at APD90 was slightly reduced in the presence of 
Nifedipine, it was not significantly different from the Fsk+IBMX-Nifedipine results (Control, 
Fsk +IBMX+Nifediepine n=4, Fsk+IBMX-Nifedipine n=6). 
5.5 Discussion 
5.5.1 Raising Extracellular Ca2+ Decreases Ventricular Conduction Velocity, While 
Decreasing Extracellular Ca2+Increases CV 
 As β-AR stimulation causes a large increase in systolic Ca2+ as well as an increase in CV, this 
study looked at the effects of raising intracellular Ca2+ independent of β-AR stimulation. 
This was achieved by raising extracellular Ca2+ from 1.8mM to 3.6mM. The effect of low 
Ca2+ on CV was also measured, by lowering extracellular Ca2+ to 1mM. The effect of raising 
extracellular Ca2+ on CV was the opposite of the effect of β-AR stimulation, where high Ca2+ 
significantly reduced CV compared to a time control (Fig. 5.3.1). Low Ca2+ also appeared to 
slightly increase CV, however this change was not significant. This results are in line with 
previous literature which suggests that raising intracellular Ca2+ decreases gap junctional 
conductance (GJC) (De Mello, 1975; Loewenstein, 1981; Spray et al., 1985). GJC is a major 
determinant of CV, and a decrease in GJC would correspond to a decrease in CV (Jongsma 
and Wilders, 2000; Shaw and Rudy, 1997). 
5.5.2 Altering Extracellular Ca2+ Did Not Affect Ca2+ transient Baseline or 
Amplitude 
Although it was expected that increasing extracellular Ca2+ would increase intracellular Ca2+ 
- which would be reflected in an increase in Ca2+ transient amplitude caused by both an 
increase in ICa and SR content (Bers, 2001, 2002) - no significant change was recorded in 
Ca2+ baseline - diastolic Ca2+ - or in Ca2+ transient amplitude (systolic Ca2+). Although a 
significant increase in Ca2+ transient amplitude is reported in Fig. 5.3.1, the result reported 
in Fig. 5.3.2 - in which the increase in Ca2+ transient amplitude is not significant - following 
background subtraction is considered the more accurate value. There is, however, both a 
trend towards increase in Ca2+ amplitude in 3.8mM Ca2+ and a trend towards a decrease in 
Ca2+ amplitude in 1mM Ca2+. The CV response to changing extracellular Ca2+ also suggests 
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that there is a change in intracellular Ca2+. It is possible that the change was too small to be 
detected by this system: the use of 360nm LED when exciting Fura-4-AM has limitations 
which are further discussed in 5.5.5. Fura-4-AM has a lower affinity for Ca2+ than its 
counterpart Fura-2: this makes Fura-4 ideal to study changes in peak Ca2+ and for studying 
the large changes in Ca2+ seen after β-AR stimulation, however it is less able to detect small 
changes in diastolic Ca2+ and therefore was possibly not the ideal choice of Ca2+ sensitive 
dye for use in these experiments. The combination of these factors may have prevented 
detection of small fluctuations in intracellular Ca2+. 
It is also clear that changes in Ca2+ caused by varying extracellular [Ca2+] are a great deal 
smaller than the large increase in Ca2+ transient amplitude (~100% increase) seen in 
response to β-AR stimulation. 
It is also important to consider that changes in extracellular [Ca2+] may affect the cardiac 
AP. Increased Ca2+ transient amplitude has been shown to increase APA in the guinea pig 
heart (Leitch and Brown, 1996). Also, increased Ca2+ could also alter intracellular Na+ via 
Na+-Ca2+ exchange. However, no change was seen in AP morphology in response to altering 
extracellular [Ca2+] (Fig. 5.3.1 G, H & I). 
5.5.3 Treatment with the L-Type Ca2+ Channel Inhibitor, Nifedipine, Decreased 
Intracellular Ca2+ but Did Not Significantly Affect CV 
The major contributor to the large increase in Ca2+ transient amplitude following β-AR 
stimulation is the increase in ICa caused by the phosphorylation of the LTCC (Bers, 2002; 
Kamp and Hell, 2000). Therefore, the LTCC inhibitor Nifedipine was used to lower systolic 
Ca2+ and determine whether this influenced CV; this also has the advantage of directly 
modifying intracellular Ca2+ without affecting extracellular Ca2+. A significant decrease in 
Ca2+ transient Inhibition of LTCC with 1μM Nifedipine demonstrated that inhibition of the 
LTCC was successful (P<0.001, control n=4, Nifedipine n=2; Fig. 5.3.1). Inhibition of the LTCC 
had no significant effect on CV (control n=4, Nifedipine n=2), however there was a trend 
towards an increase in CV in response to treatment of Nifedipine. The n of the Nifedipine 
experiments was only 2, therefore on further experiments, the increase in CV may have 
been significant. These experiments further suggest that the increase in CV in response to 
β-AR is not due to increased systolic Ca2+ and that in fact a decrease Ca2+ may increase CV.  
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5.5.4 Inhibition of the LTCC with Nifedipine Did Not Affect the CV Response to 
Fsk+IBMX 
Finally, to demonstrate that the β-AR mediated increase in CV was not mediated by 
increased ICa, Fsk+IBMX were perfused into the heart in the presence of 1μM Nifedipine. 
The CV response to Fsk+IBMX in presence of Nifedipine was not significantly different from 
the Fsk+IBMX alone (n=4). Although the change in APD90 suggests that the increase in ICa in 
response to Fsk+IBMX was not completely abolished, Fig. 5.3.1 demonstrated that 1μM 
was sufficient to reduce Ca2+ transient amplitude by ~40%. Therefore, it appears that β-AR 
mediated ICa is not a key event in the intracellular pathway responsible for increased CV. 
Nifedipine is used at a concentration of 1μM in these experiments. It is clear from 5.4.1 
that inhibition of the LTCC reduces Ca2+ amplitude. However, in 5.4.2, it does not 
significantly affect the APD90 response to Fsk+IBMX. Prolongation of APD90 is due in part 
to the affect of β-AR on the LTCC increasing ICa.. Therefore, it is clear that the LTCC is not 
completely inhibited by Nifedipine. Previous experiments carried out in isolated rabbit 
myocytes show that Nifedipine used at 1μM inhibits the LTCC at between 50-70% in the 
presence and absence of isoprenaline. So although the LTCC is significantly inhibited, the 
increase in intracellular Ca2+ is not blocked. Therefore, the increase in β-AR mediated 
increase in CV observed in Nifedipine does not eliminate a role for increased cellular Ca2+ 
as part of cAMP mediated response. 
5.5.5 Limitations of Optical Ca2+ Recordings Using 360nm and 380nm LEDs 
Fura dyes are made to be excited at 340nm and 380nm so that a ratio of the change in 
fluorescence at each of the wavelengths can be taken: taking a ratio allows for the 
reduction of artifact caused by movement and reduction of noise on the signal. In these 
experiments, the ratio of the 380nm signal and the 360nm signal are taken. The signal at 
360nm is the isobestic point - or Ca2+ insensitive part of the excitation spectrum. Using the 
isobestic point to take the ratio still cancels the movement artifact on the signal, but 
reduces the dynamic range of the indicator. 
Although the 360nm LED is more powerful than the 340nm equivalent, the maximum 
power of the 360nm LED is still low, resulting in small emission signals which are as much 
as 100x smaller than the 380 signal. This means that there is poor signal/noise ratio on the 
360nm signal and therefore noise on the 360nm signal can introduce noise on the final 
ratio. These factors combined with the lower sensitivity of Fura-4 to small changes in [Ca2+] 
may explain why it was difficult to detect changes in intracellular Ca2+ in 5.3.  
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6.Investigating the Signaling Pathway Behind a cAMP 
Mediated Increase in Conduction Velocity 
6.1 Introduction 
6.1.1 Catecholamines Signal Through Multiple Families of β-receptors on the 
Heart 
As previously discussed, the sympathetic nervous system acts on the heart through the 
release of epinephrine and norepinephrine, which bind to a group of receptors called β-
adrenergic receptors. β-receptors are G-protein-coupled receptors (GPCRs) located at the 
plasma membrane of cardiac myocytes (Bristow et al., 1986). There are multiple types of β-
AR expressed on the heart: β1-AR, β2-AR, β3-AR and β4-AR. β1-AR are the dominant type of 
β-AR in the human heart, with β1-AR expressed at a roughly 80:20 β1:β2/β3-AR ratio (Brodde 
et al., 2006; Lohse et al., 2003). Stimulation of β1 receptors generates positive chronotropic, 
isotropic and lusitropic effects on the heart. Stimulation of β2 receptors also generates 
these effects, however specific stimulation of β2 receptors cannot generate a max inotropic 
response at the same level of stimulation of β1 receptors (Brodde et al., 2006). It is thought 
this due to β1 signaling being able to generate a global rise in cAMP, whereas β2 signaling 
does not, instead giving rise only to compartmentalised increases in cAMP (Brodde et al., 
2006). It has also been shown that β2-AR stimulation does not lead to PLB or RyR2 
phosphorylation (Heijman et al., 2011; Xiao et al., 1995). β2 receptors are jointly coupled to 
both a Gs G-protein - which leads to the positive inotropic and chronotropic responses - and 
also to a Gi G-protein (Xiao et al., 1999; Xiao and Lakatta, 1993). Gi-proteins - or inhibitory 
G-proteins - lead to activation of phosphodiesterases (or PDEs), which may also limit the 
magnitude of any response to β2 stimulation (Berthouze et al., 2011). 
This study has shown a β-AR mediated increase in CV, which occurs via an increase in 
cAMP. Therefore, it is likely that this response occurs through either β1 or β2-AR mediated 
signaling. Hearts were treated with ISO (as in previous experiments) in the presence of 
either β1 or β2-AR specific inhibitors to determine whether CV is increased by either β1 or 
β2-AR stimulation. 
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6.1.2 The β1 and β2-AR Stimulatory Pathways Signal through Protein Kinase A 
and Exchange Protein Activated by cAMP 
β-ARs are GPCRs. Both β1 and β2-ARs signal through the Gs-protein. The G-protein is made 
up of the Gα, Gβ and Gγ subunits. On activation of the GPCR, the Gα subunit dissociates from 
Gβγ; in the case of the Gs-protein, Gα activates adenylyl cyclase (AC). AC converts cytosolic 
ATP to the second messenger cAMP, increasing cytosolic cAMP which in turn activates a 
number of cAMP effector proteins. The main effector of cAMP is protein kinase A (PKA), 
which, on binding to cAMP, dissociates from inhibitory subunits, allows it to phosphorylate 
target proteins. As previously discussed, there are a number of PKA targets in the heart, 
including Nav1.5 (Frohnwieser et al., 1997), the LTCC (Bers, 2001; Reuter, 1987), RyR2 (Bers, 
2002) and PLB (Bers, 2001). Cx43 contains  phosphorylation sites for multiple protein 
kinases, including PKA (Grosely et al., 2013; Lampe and Lau, 2004; Solan et al., 2007; 
TenBroek et al., 2001). As the CV response to ISO was found to be β1-AR mediated, we 
hypothethised that this increase may be PKA mediated and therefore a PKA activator and 
inhibitor were selected for the next step of this study. 
cAMP also signals via exchange proteins directly activated by cAMP (EPAC). Epac is a 
guanine nucleotide exchange factor: on binding of cAMP to Epac, Epac undergoes a 
conformational change which leads to the activation of Rap (Ras-related protein), which is 
a small GTPase (reviewed in: Edwards et al., 2012). Small GTPases are considered 'cellular 
switches' which are inactive in their GDP bound form, but become active on binding GTP. 
Activation of Epac leads to the activation of phospholipase Cε (PLCε) and also of CaMKII 
(Oestreich et al., 2009, 2007; Pereira et al., 2007), though the mechanism of this is not fully 
understood. Epacs have been shown to be activated in response to β-AR stimulation and 
play a role in the regulation of Ca2+ release in the heart (Oestreich et al., 2009), including 
phosphorylation of RyR2 (Pereira et al., 2007). 
Inhibitors of both PKA and Epac are used in this study to determine if the increase in CV 
observed is mediated by either PKA or Epac. However, inhibition studies have limitations 
due to difficulty in fully inhibiting effects at lower concentrations or potentially causing 
non-specific effects at higher concentrations. Therefore, further to the inhibitor studies, 
specific activators of PKA and Epac were used to discriminate between effects caused by 
activation of PKA and activation of Epac. Analogues of cAMP which interact specifically with 
either PKA or Epac have been developed and used in multiple studies in cardiac cells 
(Frohnwieser et al., 1997; Santillán and Boland, 1998; Somekawa et al., 2005). In this study, 
the PKA activator Adenosine- 3',5'-cyclic adenosine monophosphorothioate, Sp-isomer (Sp-
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cAMPS-AM; BioLog: Life Science Institute, Germany), which is resistant to PDE breakdown 
was used. It also contains an AM group to increase cell permeability as Sp-cAMPS is not 
lipophilic (Sandberg et al., 1991). 
The Epac specific activator used in this study was 8-Bromo-2'-O-methyladenosine-3',5'-
cyclic monophosphate (8-Br-2'-O-Me-cAMP-AM; BioLog: Life Science Institute, Germany). 
8-Br-2'-O-Me-cAMP-AM is a cell permeable variant of a cAMP analogue shown to 
specifically activate Epac  without activating PKA. (Börner et al., 2011; Komai et al., 2014). 
6.1.3 β-AR Mediated Activation of Ca2+/Calmodulin-Dependent Protein Kinase II 
β-AR stimulation has also been shown to activate the Ca2+/Calmodulin-dependent protein 
kinase II (CaMKII). As previously discussed, a PKA independent mechanism of CaMKII by β-
AR stimulation has been demonstrated to involve Epac, though the mechanism behind this 
is not fully understood (Oestreich et al., 2009, 2007; Pereira et al., 2007). CaMKII is also 
activated in a PKA dependent manner by β-AR stimulation: it has been demonstrated that 
specific activation of PKA causes activation of CaMKII and that PKA activation is required for 
phosphorylation by CaMKII at particular phosphorylation sites (Kuschel et al., 1999; Said et 
al., 2002). 
It has been suggested that the systolic increase in Ca2+ caused by β-AR stimulation may be 
responsible for the activation of CaMKII. However, in their review, Brown and Grimm 
suggest that the phasic nature of CaMKII activity makes this unlikely (Grimm and Brown, 
2010) and that CaMKII is activated by local and restricted increases in Ca2+ (Song et al., 
2008). 
CaMKII has multiple targets in EC-coupling: CaMKII has been shown to interact with PLB 
and the RyR (Currie et al., 2004; Ferrero et al., 2007) and to increase cardiac contractility 
(Wang et al., 2004) There have also been CaMKII phosphorylation sites identified on the C-
terminus of Cx43 (Huang et al., 2011): Huang et al. identify 15 different phosphorylation 
sites for CaMKII on the C-terminus of Cx43, including previously identified CaMKII 
phosphorylation sites S306, S325, S328 and S330. It has been suggested that these may 
play a role in modulating GJC (Grosely et al., 2013). 
This study looked at the effect of raising cAMP via Fsk+IBMX in the presence of the CaMKII 
inhibitor, KN-93. 
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6.2 Methods 
6.2.1 Inhibitor Studies 
To study the mechanism behind the increase in CV caused by β-AR, various inhibitors were 
used to block various components of the β-AR signaling pathway. 300nM CGP 20712A 
(Sigma Aldrich, UK) was used to block β1-AR and 100nM ICI 118, 551 (Sigma Aldrich, UK) 
was used to block β2-AR. The PKA inhibitor H-89 (Sigma Aldrich, UK) was used at 3μM to 
selectively inhibit PKA; 10μM of H-89 was used initially (data not shown), however this 
concentration of H-89 appeared to be damaging to the heart: at this concentration the 
heart became inexcitable. 5μM KN-93 (C26H29ClN2O4S · H3PO4, Sigma Aldrich, UK) was used 
to inhibit CaMKII. Due to the known non-specific effects of KN-93, the control drug KN-92 
was also used: KN-93 is the active form of the drug, whereas KN-92 (C24H25ClN2O3S · H3O4P) 
lacks the active component of the molecule and does not inhibit CaMKII – this allows it to 
work as a negative control for KN93. Finally, a new inhibitor of Epac1, CE3F4 (Courilleau et 
al., 2012), was kindly donated by Professor Fischmeister, Université Paris-Sud. This was 
used at 40μM, as directed, however, this inhibitor had not previously been used in the 
intact heart. 
Inhibitors were perfused onto the heart with Tyrode's solution at least 10min prior to β-AR 
stimulation. A control recording was taken immediately prior to drug addition and then 
Fsk+IBMX was perfused into the heart for 5 min, as in previous experiments. 
6.2.3 Analogues of cAMP  
As previously mentioned in 6.1.2, analogues of cAMP which are designed to specifically 
activate either PKA or Epac - without binding to other downstream effectors of cAMP - 
were used to determine whether the recorded increase in CV was PKA or Epac mediated. 
The PKA activator Sp-cAMPS-AM was used at 24μM in line with concentrations used in 
previous studies (Sandberg et al., 1991; Santillán and Boland, 1998), however this analogue 
of cAMP had not previously been used in the intact heart. The Epac activator, 8-Br-2'-O-
Me-cAMP-AM, was used at 10μM. Studies site using 8-Br-2'-O-Me-cAM at a range of 
concentrations from between 20μM and 1mM (Börner et al., 2011; Komai et al., 2014). Due 
to the large volumes of drug needed in whole heart experiments, 10μM was used to allow 
the n numbers required for these experiments. Again, this drug had not previously been 
used on the intact heart. 
As the cell permeable variants of these drugs require the removal of acetomethyl group by 
intracellular esterases, these drugs were perfused on for 10min rather than the 5min used 
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in previous experiments. They were perfused on using the same syringe driver setup 
described in 2.6. 
Results 
6.3 β-AR Mediated Increase in Conduction Velocity is via β1 
adrenoreceptors 
The heart was pretreated with either 300nM CGP 20712A (CGP), an inhibitor of β1-ARs, or 
100nM ICI 118, 551 (ICI), an inhibitor of β2-ARs. The heart was then treated with 100nM ISO 
as in previous experiments. In the presence of ICI, CV increased in response to ISO by 
9.6±3.0%, which was not significantly different from the response to ISO without inhibitor 
(ISO n=6,  ISO+β-inhibitors n=4; Fig 6.3.1 B). Treatment with CGP significantly reduced the 
CV response to ISO: ISO increased CV by only 2.6±3.6% in presence of CGP compared to 
11.9±5.1 without CGP (p<0.001, ISO n=6, ISO+β-inhibitors n=4). Inhibition with ICI had no 
significant effect on the APA response to ISO: ISO increased APA by 5.1±6.5% in the 
presence of ICI vs. 10.3±5.6% without (n.s., n=4; Fig. 6.3.1 C). CGP completely abolished any 
increase in APA in response to ISO (p<0.05, n=4). 
Inhibition with either ICI or CGP produced no effect on the TRise of the APD90 response to 
ISO (n=4, Fig. 6.3.1 D and E). The increase in Ca2+ transient amplitude in response to ISO was 
reduced in the presence of CGP (p<0.05, n=4; Fig. 6.3.1 G): ISO alone increased Ca2+ 
transient amplitude by 62.3±5.4% at its maximal response, whereas ISO in presence of CGP 
increased Ca2+ transient amplitude by only 22.3±17%.  ICI appeared to slightly reduce the 
increase in Ca2+ transient amplitude, with Ca2+ amplitude reaching 53.3±15.8% at its max 
response, however the change is not significant (n=4). Shortening of the Ca2+at 90% in 
response to ISO was significantly decreased by CGP, with Ca2+duration being shortened by 
only 7.4±4.5% by ISO in the presence of CGP compared to 17.1±1.1% with ISO alone 
(p<0.05, n=4; Fig. 6.3.1 H). Again, ICI had no significant effect on Ca2+ duration shortening 
(n=4). 
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Fig. 6.3.1 β-AR mediated increase in CV is via β1-AR. 
A) Example CV traces taken from individual experiments. Traces show a heart treated with ISO alone 
(black), a heart treated with ISO after preincubation with 300nM CGP 20712A (grey), a β-1 inhibitor, 
and a heart treated with ISO after pre-incubation with 100nM ICI 118, 551 (red), a β-2 inhibitor. B) 
Pre-treatment with CGP 20712A significantly reduces the CV response to ISO (60-120s p<0.05 or less, 
150-300s p<0.001; ISO n=6; ISO+β-inhibitors n=4). Pre-treatment with ICI 118, 551 does not 
significantly alter the CV response to ISO (ISO n=6, ISO+β-inhibitors n=4). The increase in CV in 
response to ISO is significantly greater in hearts pretreated with ICI 118, 551 vs hearts treated with 
CGP 20712A (150-300s p<0.05 or less, n=4). C) Inhibition with ICI 118, 551 appeared to reduce the 
effect of ISO on APA, however this difference was not significant (n=4). CGP 20712A significantly 
reduced the effect of ISO on APA (120s p<0.05, n=4). D, E) Pre-incubation with CGP 20712A or ICI 
118, 551 had no effect on TRise or the effect of ISO on APD90. F) Pre-incubation with CGP 20712A or 
ICI 118, 551 had no effect on Ca2+ baseline. G) The increase in Ca2+ transient amplitude in response to 
ISO is reduced in the presence of CGP 20712A (120s p<0.05, n=4).  ICI 118, 551 also appears to slight 
reduce the increase in Ca2+ transient amplitude, however the change is not significant. H) Shortening 
of the Ca2+at 90% in response to ISO is significantly decreased by CGP 20712A (120-300s p<0.05, 
n=4). ICI 118, 551 does not significantly alter the CaD response to ISO. 
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6.4 Inhibition with the PKA Inhibitor H-89 Does Not Affect the CV 
Response to Forskolin and IBMX  
Hearts were pre-treated with the PKA inhibitor H-89 and then treated with Fsk+IBMX to 
raise intracellular cAMP to determine if the β-AR mediated increase in CV occurred via PKA. 
Inhibition of H-89 had no significant effect on the CV response to raising cAMP (Fsk+IBMX-
H-89 n=6, Fsk+IBMX+H-90 n=5; Fig. 6.4.1 B). 
 
 
Fig. 6.4.1 Inhibition of PKA via H-89 does not alter the CV response to raised cAMP via Fsk+IBMX. 
 A) Example CV traces taken from individual experiments. Traces show a heart treated with Fsk+IBMX 
alone (black) and a heart treated with Fsk+IBMX after preincubation with 3μM H-89 (grey). B) Pre-
treatment with 3μM H-89 does not significantly affect the CV response to Fsk+IBMX (Fsk+IBMX-H-89 
n=6, Fsk+IBMX+H-89 n=5). C) Pre-incubation with H-89 significantly reduced APD90 prolongation by 
Fsk+IBMX (p<0.01 Fsk+IBMX-H-89 n=6, Fsk+IBMX+H-89 n=5). 
Incubation with H-89 reduced APD90 prolongation in response to raising cAMP: APD90 was 
prolonged by 18.6±6.4% in the presence of H-89 and by 31.9±6.9% by Fsk+IBMX alone 
(p<0.01 Fsk+IBMX-H-89 n=6, Fsk+IBMX+H-89 n=5; Fig. 6.4.1 C). 
 
6.5 Inhibition with the CaMKII Inhibitor KN-93 Reduces the CV 
Response to Forskolin and IBMX  
Hearts were pre-incubated with either the CaMKII inhibitor KN-93 or the control drug KN-
92: KN-93 (C26H29ClN2O4S · H3PO4) is the active form of the drug, whereas KN-92 
(C24H25ClN2O3S · H3O4P) lacks the active component of the molecule and does not inhibit 
CaMKII – this allows it to work as a negative control for KN93. Inhibition with KN-93 
significantly reduced the CV response to Fsk+IBMX: Fsk+IBMX increased CV by 12.1±5%, 
whereas CV was only increased by 3.2±1.8% in the presence of KN-93 (p<0.001 
Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5; Fig. 6.5.1). There was no significant difference 
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between KN-92 and Fsk+IBMX alone (p<0.001 Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5). 
KN-93 also significantly reduced the prolongation of the APD at 90% in response to 
Fsk+IBMX: Fsk+ IBMX alone prolong the APD90 by 31.9±6%, whereas APD is prolonged by 
21.1±10.5% in the presence of KN-93 (p<0.05 Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5; 
Fig. 6.5.1). However, KN-92 also reduced APD prolongation in response to Fsk+IBMX, 
prolonging APD90 by only 12.1±3.7% (p<0.01 Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5). 
This suggests that there was a non-specific interaction between KN-92 - and therefore likely 
also KN-93 - and APD. 
 
Fig. 6.5.1 Inhibition of CaMKII via KN-93 significantly reduces the CV response to raised cAMP via 
Fsk+IBMX. 
A) Example CV traces taken from individual experiments. Traces show a heart treated with Fsk+IBMX 
alone (black) and a heart treated with Fsk+IBMX after preincubation with 5μM KN-93 (grey), and a 
heart treated with Fsk+IBMX after pre-incubation with the control peptide KN-92 (red). B) Pre-
treatment with 5μM KN-93 significantly decreases the CV response to Fsk+IBMX (150-180 p<0.05 or 
less, 210-300s p<0.001; Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5). KN-92 did not significantly 
affect the CV response to Fsk+IBMX. C) Pre-incubation with KN-93 significantly reduced APD90 
prolongation by Fsk+IBMX (120s p<0.05, Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5).  However, the 
control peptide KN-92 also significantly decreased the APD90 response to Fsk+IBMX (90-300 
p<0.05or less; Fsk+IBMX±KN-93 n=6, Fsk+IBMX+KN-92 n=5). 
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6.6 Inhibition with the Epac1 Inhibitor CE3F4 Does Not Affect the CV 
Response to Forskolin and IBMX 
Hearts were pretreated with the Epac1 inhibitor CE3F4 and then treated with Fsk+IBMX 
over 5min. Incubation with the Epac1 inhibitor had no effect on the CV response to 
Fsk+IBMX (Fsk+IBMX- CE3F4 n=6, Fsk+IBMX+ CE3F4 n=3; Fig.6.6.1 B). Pre-incubation with 
CE3F4 appeared to reduce APD prolongation at 90%: Fsk+IBMX alone prolonged APD90 by 
12.6±8, whereas APD90 was prolonged 5.6±4.3% in the presence of CE3F4, however this 
difference was not significant (Fsk+IBMX- CE3F4 n=6, Fsk+IBMX+ CE3F4 n=3; Fig. 6.6.1 C). 
 
Fig. 6.6.1 Inhibition of Epac1 via CE3F4 does not alter the CV response to raised cAMP via 
Fsk+IBMX. 
A) Example CV traces taken from individual experiments. Traces show a heart treated with Fsk+IBMX 
alone (black) and a heart treated with Fsk+IBMX after preincubation with 40μM CE3F4 (grey). B) Pre-
treatment with 40μM CE3F4 does not significantly affect the CV response to Fsk+IBMX (Fsk+IBMX- 
CE3F4 n=6, Fsk+IBMX+ CE3F4 n=3). C) Pre-incubation with CE3F4 appears to reduce APD90 
prolongation by Fsk+IBMX, however the change was not significant (Fsk+IBMX- CE3F4 n=6, 
Fsk+IBMX+ CE3F4 n=3). D) Pre-treatment with 40μM CE3F4 does not significantly affect the baseline 
of the Ca2+ transient (Fsk+IBMX- CE3F4 n=6, Fsk+IBMX+ CE3F4 n=3). E) Pre-incubation with CE3F4 
appears to reduce the increase in Ca2+ transient amplitude by Fsk+IBMX, however the change was 
not significant (Fsk+IBMX- CE3F4 n=6, Fsk+IBMX+ CE3F4 n=3). F) ) Pre-treatment with CE3F4 does not 
significantly affect Ca2+ duration at 90%  (Fsk+IBMX- CE3F4 n=6, Fsk+IBMX+ CE3F4 n=3). 
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6.7 PKA specific cAMP analogue SpcAMPS-AM Increases Conduction 
Velocity in the Intact Rat Heart 
Analogues of cAMP which specifically activate either PKA (Sp-cAMPS) or Epac (8-Br-2'-O-
Me-cAMP-AM - referred to as 8-Br-AM from this point) were perfused into the heart to 
determine whether the increase in CV in response to β-AR was a PKA or Epac1 mediated 
response. The analogues of cAMP used in these experiments were -AM cell permeable 
variants of the drugs, therefore they were perfused on for 10min - rather than 5min - as 
cleavage of the acetomethyl group would mean these drugs would take longer to work. 
The Fsk+IBMX trace shown for comparison contains only 5min of drug incubation. The 
DMSO control trace also shows only 5min of addition of DMSO, however a further 5min 
washout period is displayed as a time-control. 
CV was significantly increased by the PKA specific analogue, SpcAMPS (Fig. 6.7.1 B). 
SpcAMPS showed a maximal increase in CV of 10.9±3.5% (p<0.001 Fsk+IBMX n=6, DMSO, 
SPcAMPS-AM, 8-Br-AM n=4). This increase was comparable to the increase of 12.1±2.5% 
seen in response to Fsk+IBMX. 8-Br-AM had no effect on CV (Fsk+IBMX n=6, DMSO, 
SPcAMPS-AM, 8-Br-AM n=4). SpcAMPS significantly prolonged APD90 by 8.9±4.4% (p<0.05 
Fsk+IBMX n=6, DMSO, SPcAMPS-AM, 8-Br-AM n=4; Fig. 6.7.1 C), though APD90 by 
SpcAMPS was significantly less than APD90 prolongation by Fsk+IBMX (p<0.1 Fsk+IBMX 
n=6, DMSO, SPcAMPS-AM, 8-Br-AM n=4). 8-Br-AM showed no significant difference from 
the DMSO control (Fsk+IBMX n=6, DMSO, SPcAMPS-AM, 8-Br-AM n=4). 
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Fig. 6.7.1 Treatment with the PKA-specific cAMP analogue, SPcAMPS-AM, significantly increases 
CV over 10 minutes 
A) Example CV traces taken from individual experiments. Traces show DMSO control in black, a heart 
treated with Fsk+IBMX in grey, a heart treated with the PKA specific cAMP analogue SPcAMPS in red, 
and a heart treated with the Epac specific cAMP analogue 8-Br-2'-O-Me-cAMP-AM (8-Br-AM) in blue 
. B) 24μM SPcAMPS-AM significantly increases CV. 10μM 8-Br-AM was not significantly different 
from the DMSO control. (270s-330s p<0.05 or less, 330-600s p<0.001; Fsk+IBMX n=6, DMSO, 
SPcAMPS-AM, 8-Br-AM n=4). C) SPcAMPS significantly prolonged APD90, though not to the same 
extent as Fsk+IBMX. 8-Br-AM was not significantly different from the DMSO control (360s, 480-600s 
p<0.05, Fsk+IBMX n=6, DMSO, SPcAMPS-AM, 8-Br-AM n=4). 
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6.8 Discussion 
6.8.1 β1-AR stimulation Increases Ventricular CV 
Inhibition with the β1-AR inhibitor CGP almost completely abolished the CV response to ISO 
(Fig. 6.3.1). β2-AR inhibition has no significant impact on the CV response to ISO. This 
suggests that CV is modulated by β-AR specifically through β1-ARs. However, β2-AR 
inhibition also had no effect on the AP or Ca2+ transient. Although the inotropic effects of 
β2-AR stimulation are less than β1-AR stimulation, it is expected that β2 inhibition would 
lead to a slight decrease in Ca2+ amplitude and a slight reduction in APD prolongation. In 
these experiments, no significant difference was observed, suggesting it is possible that β2-
AR were not successfully being inhibited. 
Therefore, although this study demonstrates that CV is regulated by β-AR through β1-AR, it 
does not show that CV is not regulated through β2-AR. 
6.8.2 β-AR Stimulation Increases CV by a PKA Mediated Response 
The PKA specific activator SpcAMPS significantly increased CV to a similar magnitude to 
Fsk+IBMX (Fig. 6.7.1). This cAMP anologue has been shown to be highly specific to PKA 
activation (Sandberg et al., 1991). Therefore, it is possible to conclude that β-AR 
stimulation increases ventricular CV via a cAMP and PKA mediated pathway. Although 
inhibition with the PKA inhibitor H-89 had no effect on the CV response to Fsk+IBMX, using 
inhibitors is a less accurate way to study the mechanism behind this response than using a 
specific activator of PKA: it is not possible to ensure that PKA is entirely inhibited by H-89 in 
this intact preparation, and it is also not known to which extent PKA would need to be 
inhibited to prevent the CV response. Although it is clear from the APD90 response that H-
89 is having an effect on the heart, it was clearly not to a high enough extent to block PKA 
mediated changes in AP characteristics, this suggests there is a significant remnant PKA 
activity that couple mediate the CV response observed. 
As previously discussed, PKA interacts with numerous targets in EC-coupling, including 
Nav1.5, which is phosphorylated to increase INa (Frohnwieser et al., 1997; Lu et al., 1999; 
Matsuda et al., 1992). This may account for some of the increase in CV, however - as 
previously discussed in 4.6.1 - the magnitude of change recorded in APA is not sufficient to 
explain the full increase in CV. 
Cx43 has been shown to contain phosphorylation sites for PKA (reviewed by Lampe and 
Lau, 2004; Solan et al., 2007; TenBroek et al., 2001). Phosphorylation by PKA at S365 has 
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been suggested to cause an increase in GJC and also to prevent the down-regulation of GJC 
through phosphorylation by PKC (Solan et al., 2007). This is in line with previous studies 
which suggest that β-AR increases GJC (Burt and Spray, 1988; Mehta et al., 1992; Salameh 
et al., 2006) and studies which suggest that PKA activation increases GJC (Somekawa et al., 
2005). 
6.8.3 Epac activator 8-Br-2'-O-Me-cAMP-AM Did Not Increase CV 
The Epac activator 8-Br-2'-O-Me-cAMP-AM did not have any effect on CV (Fig. 6.7.1). The 
Epac activator also had no effect on APD90. A low concentration of this drug was used and 
it has never been used in the intact heart before, therefore it is difficult to ascertain 
whether 8-Br-AM successfully reached the cardiac myocytes at a concentration to have an 
effect. There are conflicting reports suggesting that Epac has no effect on APD (Hothi et al., 
2008) and also that Epac prolongs APD in the rat heart (Brette et al., 2013), therefore it is 
difficult to ascertain if 8-Br-AM had any effect via other likely EPAC targets. 
The inhibitor of Epac1, CE3F4, also had no impact on the CV response to Fsk+IBMX (Fig. 
6.6.1), supporting that this is not an Epac1 mediated response. It also had no significant 
impact on the APD90 prolongation. CE3F4 also had no significant impact on the Ca2+ 
transient. Epac is known to have a role in Ca2+ regulation in the heart. Literature suggests 
that activation of Epac decreases the Ca2+ transient amplitude (Hothi et al., 2008; Pereira et 
al., 2007), meaning that inhibition of Epac would cause an increase in Ca2+ amplitude. 
However, it is possible this increase was masked by the already large increase in Ca2+ 
amplitude caused by Fsk+IBMX and PKA mediated effects. So it is again difficult to ascertain 
if CE3F4 was having any effect on the heart. 
Due to the magnitude of the PKA mediated CV response, it seems probable that this 
response is PKA and not Epac mediated. However, to fully investigate the role of Epac in 
this response, further experiments are required. For example, experiments using higher 
concentrations of the Epac activator while also taking Ca2+ transient recordings may give a 
better indication of whether the Epac activator is reaching the heart. 
6.8.4 CaMKII May Play a Role in the β-AR Mediated Increase in CV 
Inhibition with the CaMKII inhibitor KN-93 greatly reduced the CV response to Fsk+IBMX. 
This suggests that CaMKII is involved in the regulation of CV by β-AR stimulation. Recent 
studies have identified CaMKII phosphorylation sites on the C-terminus of Cx43 (Huang et 
al., 2011), however the role of CaMKII phosphorylation of Cx43 is unknown. Based on the 
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results of this study, CaMKII could be activated in a PKA dependent manner and both 
CaMKII and PKA phosphorylate targets which increase CV. 
However, although the control peptide KN-92 had no effect on the CV response to 
Fsk+IBMX, KN-92 significantly reduced APD90 prolongation by Fsk+IBMX. These results 
suggest that there are non-specific effects of KN-92 - and therefore KN-93 - occurring. 
Although these don't appear to affect CV, it would be important to verify these results in 
further experiments using a different CaMKII inhibitor, such as Autocamtide 2-related 
inhibitory peptide (AIP). 
In summary, attempts to modulate the cAMP mediated CV response using specific 
inhibitors of A-kinase and CaMkinase pathways proved equivocal. However, strong 
evidence for an A-kinase mediated changes was obtained using an A kinase specific cAMP 
analogue which strongly suggests that this is the dominant pathways used to modulate β1-
mediated changes in myocardial CV.  
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7. Discussion 
7.1 Conclusions 
This study aimed to investigate the effect of β-AR stimulation on ventricular CV. It found 
that β-AR stimulation via ISO caused an increase in left ventricular CV of approximately 8%. 
This increase in CV was found to be cAMP mediated, with Fsk+IBMX increasing CV by 
between 8-12%. This effect was not due to changes in Ca2+ handling and, although an 
increase in action potential amplitude (APA) was recorded, it was determined that changes 
in INa were likely not sufficient to explain the change in CV. This suggested a potential role 
for GJC in mediating these changes in CV. The role for GJC needs to be further investigated: 
methods by which this could be done are discussed in 7.3. 
β1AR stimulation was shown to be responsible for the increase in CV, though the role of β2-
AR signaling could not be completely ruled out. The β1AR signals through raising cAMP, and 
the increase in CV was shown to be mediated through the cAMP sensitive kinase, PKA. This 
was demonstrated using the PKA activator SP-cAMPS, whereas the inhibitor of PKA – H-89 
– had no effect. We suggest that the use of a specific activator is a more accurate way to 
assess the involvement of PKA in this pathway, as it is not possible to tell if PKA was fully 
inhibited by H-89. Epac was not shown to have a role in this pathway. The increase in CV in 
response to β-AR stimulation was also shown to be at least partially CaMKII dependent: 
inhibition of CaMKII significantly reduced the CV response to raising cAMP. However, this 
change was accompanied by non-specific effects of KN-92/93 on APD and therefore further 
experiments are required to validate this. 
7.2 PKA Phosphorylation Sites Which Modulate CV 
As the increase in CV in response to β-AR stimulation has been demonstrated to be 
mediated by PKA, it is important to discuss PKA phosphorylation sites which may affect CV 
and the mechanisms by which PKA may regulate CV. 
As previously discussed, NaV1.5 is known to be phosphorylated by PKA. The 
phosphorylation of NaV1.5 increases INa, which would be seen in these experiments as an 
increase in APA and dV/dtmax. An increase in APA of 11% was recorded but no change in 
dV/dtmax or TRise was recorded in these experiments. As previously discussed, APA is not an 
ideal method by which to estimate INa, as literature has suggests that it may also be 
influenced by increased Ca2+ transient amplitude (Leitch and Brown, 1996; Niedergerke and 
Orkand, 1966). However, if it is assumed the 11% increase in APA does correspond to an 
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equivalent increase in INa, this would increase dV/dtmax by approximately 5%. Since dV/dtmax 
is proportional to CV2, the effect of β-AR stimulation on INa would only increase CV by 
approximately 2%. Therefore, the estimated change in INa caused by acute β-AR stimulation 
over this time-period is insufficient to explain the ~10% increase in CV. The literature has 
not come to a consensus on this point, e.g. recordings from neonatal cardiomyocytes 
suggest that the increase on CV is caused entirely by an increase in dV/dtmax (de Boer et al., 
2007), while in a separate study on the same preparation (Darrow et al., 1996), increased 
CV was independent of increased in dV/dtmax. 
Therefore, the role of other PKA phosphorylation targets must be considered. Cx43 is the 
dominant Cx in the ventricle. Cx43 has been demonstrated to be a phosphoprotein, which 
has multiple phosphorylation sites for multiple different kinases. This includes multiple 
phosphorylation sites for PKA in the C-terminal tail of the protein: S373, S369, S365 and 
S364 (Lampe and Lau, 2004; Solan et al., 2007; TenBroek et al., 2001). Cx43 turnover is 
highly dynamic in the heart, as Cx43 has a half-life of only 1-2 hours (Beardslee et al., 1998; 
Laird et al., 1991) and Cx43 has shown to be variably phosphorylated throughout its 
lifetime (Chen et al., 2013). cAMP has been shown both to upregulate the amount of Cx43 
at the intercalated disc (Somekawa et al., 2005; TenBroek et al., 2001); this could be due to 
increased transcription of Cx43, as shown in neonatal rat cardiac myocytes (Salameh et al., 
2006) or through trafficking of Cx43 to the intercalated disc (Paulson et al., 2000b).  
Phosphorylation of Cx43 has also been shown to increase GJ permeability. Solen et. al 
demonstrated that phosphorylation of S365 on Cx43 not only increased conductance of 
GJs, but also that S365 phosphorylation prevented phosphorylation of Cx43 by PKC at a site 
which decreased GJC (Solan et al., 2007). Somekawa et al. showed that activation of PKA 
using a cAMP specific analogue (6Bnz) led to an increase in GJC without changing the levels 
of Cx43 at the intercalated disc, suggestion an increase in GJ permeability (Somekawa et al., 
2005). 
There has been very little work looking at Cx43 and its phosphorylation state following β-
AR in adult cells. Western blotting with the use of phospho-specific antibodies could be 
carried out on tissue which is snap frozen immediately following drug addition. Western 
blots could also be carried out on isolated cardiac myocytes treated with specific activators 
of PKA. Further to this, studying the localisation of both Cx43 and phospho-Cx43 following 
β-AR stimulation, using confocal microscopy and fluorescent antibodies, could give an 
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indication of whether any change in CV is due to GJ open probability or changes in GJ 
plaque size. 
7.2.1 The Role of CaMKII 
Activation of PKA can also lead to the activation of Ca2+/calmodulin-dependent protein 
kinase II (CaMKII) (Kuschel et al., 1999; Said et al., 2002). This study demonstrated that 
inhibition of CaMKII by KN-93 significantly reduced the CV response to raising cAMP, 
however there were concerns about the non-specific effects of KN-93/92, therefore further 
experiments are required. Recently, 15 CaMKII phosphorylation sites have been identified 
on Cx43 by mass spectroscopy (Huang et al., 2011), but the function of phosphorylation of 
Cx43 by CaMKII is unknown. 
7.3 β-AR May Regulate CV Via GJC 
One possible mechanism by which to explain the change in CV in response to β-AR is 
changes in GJC. Though these experiments have not measured GJC, the lack of a sufficient 
increase in dV/dtmax to explain this change presents GJC as a likely candidate to explain 
these changes. However, it is important to consider that the relationship between GJC and 
CV is not linear: at low levels of GJC, there is a far greater effect on CV than at GJC under 
normal conditions, as demonstrated by computer simulations by Jongsma and Wilders 
(Jongsma and Wilders, 2000). Fig. 7.3.1 shows the relationship between CV and GJC 
(represented as gj below) (Jongsma and Wilders, 2000). This simulation suggests that to 
increase CV from 60cm/s to 70cm/s - values within the normal range of CV in mammals - 
would take an increase in GJC of ~50%.  
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Fig. 7.3.1 Simulations of the effect of gap junctional conductance (gj) on conduction velocity 
(Jongsma and Wilders, 2000).  
Directional changes in CV shown as a function of gj. Annotated by Valderrábano et al. to highlight 
the difference in gj modulation of CV between longitudinal and transverse CV: a 50% decrease in gj 
generates a 13% decrease in longitudinal CV vs. a 36% decrease in transverse CV (Valderrábano, 
2007). 
It also shows that changes in GJC do not affect transverse conduction velocity (CVT) and 
longitudinal (CVL) equally. Longitudinal conduction velocity is conduction along the fibre 
orientain - ie. along the long axis of the cell. This has a higher proportion of cytoplasmic 
conduction vs. conduction across the intercalated disc and is overall lower resistance than 
in the transverse direction. With transverse conduction, conduction crosses a higher 
proportion of intercalated discs vs. cytoplasm. This is a higher resistance path - 
demonstrated by lower CV - but also a path which is more influenced by GJC. This is also 
demonstrated by computational modeling carried out by Martin Bishop, King's College, UK 
(Fig. 7.3.2). His modeling demonstrates that increasing GJC has a greater influence of CVT 
than CVL, whereas varying intracellular conductance has a greater influence on CVL than 
CVT. 
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Figure 7.3.2:  Computational modelling of longitudinal and transverse conduction (Dr. Martin 
Bishop, King's College, UK). 
A.) Schematic representation of an idealised cuboid cell of length lcell, width dcell, showing resistance 
to current flow along and transverse to the cell’s length where Rcl is the cytoplasmic resistance along 
the cell, Rct is the cytoplasmic resistance transverse to the cell and Rj is the resistance of the gap 
junction. B.) Variation in CV as gap junction conductivity is varied and C.) Variation in CV as 
intracellular conductivity is varied. 
This suggests that if CV was recorded in a transverse direction rather than a longitudinal 
direction, then a greater increase in CV in response to β-AR would be recorded. Some initial 
experiments were carried out during this study to investigate this. Fig.7.3.3 shows CV 
response to 5min of ISO, carried out as described in previous experiments. Recordings were 
made in the transverse direction rather than the longitudinal - this was achieved by first 
locating the point of highest CV (CVL) and then rotating the electrode 90⁰. Initial 
experiments show an increase in CVT of 23±7.9% compared to the 8-10% response 
recorded in the longitudinal direction (Fig. 7.3.3 B). However, locating the angle at which 
CVT is completely transverse to the electrode is more difficult than locating the direction of 
longitudinal conduction, and therefore the transverse response to β-AR was highly variable 
and the difference between CVL and CVT was not significant (n=4), though further 
experiments are required to account for variability. 
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Fig. 7.3.3 The ISO CV response is greater in the transverse vs. longitudinal direction, but the 
difference is not significant. 
A) Example CV traces taken from individual experiments. Traces show a heart treated with ISO where 
CV was measured in line with fibre orientation, longitudinally (black), and a heart treated with ISO 
where CV was measured at right angles to the fibre orientation, transversely (grey). B) The increase 
in transverse CV in response to ISO appears greater than the increase in CV in the longitudinal 
direction, however this difference is not significant (n=4) C) Recording APD90 in the longitudinal or 
transverse direction has no effect on APD90 (n=4). 
The next logical step in this study would be to find a way to measure the effect of β-AR 
stimulation on GJC. Though this has been carried out in isolated pairs of cells or in 
monolayers of neonatal rat cardiac myocytes, this has not been carried out in the intact 
heart. 
One way to approach this would be to measure space constant: recording the distance a DC 
electrical signal can travel through the myocardium.  This would involve using a 
subthreshold pulse at one point on the surface of the myocardium, and then measuring the 
rate at which this pulse degrades as it travels away from the point of stimulation. This 
would give an indication of the resistance of the myocardium and therefore GJC. 
Experiments could be carried out in more linear models – such as trabeculae – to simplify 
the study and allow the application of linear cable theory. 
Another possible technique has been used in the myocardium to measure myocardial 
impedance and calculate GJ resistivity (Dhillon et al., 2013): in this technique, cardiac 
myocardium was coated with mineral-oil gel and an electrical current was passed through 
both the myocardium and an extracellular shunt. The impedance of the entire system was 
measured, and resistance was measured using two electrodes in the myocardium which 
were a known distance apart. The impedance of the extracellular shunt was known, and 
from this it was possible to calculate impedance of the myocardium. Longitudinal 
impedance was calculated as both sarcoplasmic resistance and GJ impedance, and from 
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this it was possible to calculate GJ resistance. Use of a method such as this would allow the 
study of the effect of β-AR on GJC while still studying the intact myocardium, which is 
essential when looking at the effect on CV in the adult heart. 
Substances that modulate GJC – such as the gap junction inhibitors heptanol and 
carbenoxolone – could also be used to inhibit GJC. If the increase in CV in response to β-AR 
stimulation were GJ mediated, it is possible that inhibition of GJC would attenuate the CV 
response. However, there are few compounds that modulate purely GJC without also 
altering the electrophysiology of the heart. 
Although it is important to study CV in intact tissue, this work could also be supported by 
experiments carried out in pairs of cells or cell monolayers (Burt and Spray, 1988; 
Somekawa et al., 2005). This would also allow the use of drugs which we were unable to 
use in the intact heart, either due to cost constraints or due to the drug appearing not to 
reach the tissue: these include the specific inhibitor of CaMKII, AIP, and other cAMP 
analogues which specifically activate PKA or EPAC. 
Investigating both the effect of β-AR stimulation on Cx43 itself and also how this affects GJC 
would give a better idea of how the β-AR pathway regulates CV. 
7.4 Regulation of CV in Heart Failure 
As previously discussed, understanding the regulation of CV is an important part of 
understanding both arrhythmogenesis and how re-entrant circuit arrhythmias are 
maintained. A key model for understanding this is the 'wavelength' theory. CV x ERP is 
defined as the cardiac wavelength. A lower wavelength promotes the generation and 
maintenance of re-entrant circuit arrhythmias. Therefore, a lower CV could contribute to 
arrhythmogenesis and in principle, a higher CV could be anti-arrhythmic. 
Uncoupling of GJs has been demonstrated to occur in ischaemic regions of the heart 
(Kléber et al., 1987), which profoundly reduces CV. In surviving regions of the heart, 
remodeling of gap junctions has been shown to occur in heart failure in humans (Severs et 
al., 2004; J. Smith et al., 1991) and in animal models (Matsushita et al., 1999). Alongside 
this, β-AR signaling, particular β1ARs, has also been demonstrated to be down-regulated in 
heart failure (Lohse et al., 2003a; Nikolaev et al., 2010). Therefore, understanding the 
regulation of CV by β-AR stimulation in heart failure could be key to understanding the 
changes in disease which lead to the generation of arrhythmias. 
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In addition to experiments on normal myocardium, experiments looking at the effect of β-
AR stimulation in heart failure models would be an interesting next step. A routine 
observation in failing hearts is β-AR desensitization within the ventricle: this occurs through 
multiple mechanisms in which β-ARs are uncoupled from Gs protein. Phosphorylation of the 
GPCR by PKA and G receptor kinases (GRKs) lead to decreased association of Gs and 
increased association with the inhibitory G protein (Gi) and also increases recruitment of β-
arrestin (Ungerer 1994, 1993). This is more pronounced in β2AR signaling and therefore the 
decreased ratio of β1:β2 in heart failure amplifies this effect (Lohse et al., 2003b). Lower 
levels of Gs and higher levels of Gi are expressed in heart failure (Ping et al., 1997). 
Therefore, β-AR signaling is greatly altered in the ventricle in heart failure. Potentially, if the 
modified β-AR response in HF has a lowered or absent CV compoenent, the absence of a 
higher CV may contribute to the pro-arrhythmic status of the myocardium. As explained 
elsewhere (Section 3.6.2) decreased electrical wavelength increases the opportunity for re-
entrant arrhythmias, a pathological β-AR response that involved a decreased APD without 
an increased CV may result in a critically reduced electrical wavelength. Further work is 
required to investigate whether this novel mechanism applies in HF. The study would 
involve direct measurements of ECG in vivo, electrophysiology and CV in vitro and Western 
Blot analysis of tissue to determine the phosphorylation state of Cx43 in heart failure 
models.  
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